Patent Grant
9101384
The present invention relates generally to medical devices and methods and more particularly to minimally invasive, catheter based devices, systems and methods for treating sinusitis and other ear, nose & throat disorders, and which reduce the need to provide fluoroscopic or other radiographic visualization.
The human nose is responsible for warming, humidifying and filtering inspired air and for conserving heat and moisture from expired air. The nose is also an important cosmetic feature of the face. The nose is formed mainly of cartilage, bone, mucous membranes and skin. The right and left nostrils lead into right and left nasal cavities on either side of the intranasal septum. The right and left nasal cavities extend back to the soft palate, where they merge to form the posterior choanae. The posterior choanae opens into the nasopharynx. The roof of the nose is formed, in part, by a bone known as the cribriform plate. The cribriform plate contains numerous tiny perforations through which sensory nerve fibers extend to the olfactory bulbs. The sensation of smell occurs when inhaled odors contact a small area of mucosa in the superior region of the nose, stimulating the nerve fibers that lead to the olfactory bulbs.
The paranasal sinuses are cavities formed within the bones of the face. The paranasal sinuses include frontal sinuses, ethmoid sinuses, sphenoidal sinuses and maxillary sinuses. The paranasal sinuses are lined with mucous-producing epithelial tissue. Normally, mucous produced by the linings of the paranasal sinuses slowly drains out of each sinus through an opening known as an ostium, and into the nasopharynx. Disorders that interfere with drainage of mucous (e.g., occlusion of the sinus ostia) can result in a reduced ability of the paranasal sinuses to function normally. This results in mucosal congestion within the paranasal sinuses. Such mucosal congestion of the sinuses can cause damage to the epithelium that lines the sinus with subsequent decreased oxygen tension and microbial growth (e.g., a sinus infection).
The nasal turbinates are three (or sometimes four) bony processes that extend inwardly from the lateral walls of the nose and are covered with mucosal tissue. These turbinates serve to increase the interior surface area of the nose and to impart warmth and moisture to air that is inhaled through the nose. The mucosal tissue that covers the turbinates is capable of becoming engorged with blood and swelling or becoming substantially devoid of blood and shrinking, in response to changes in physiologic or environmental conditions. The curved edge of each turbinate defines a passageway known as a meatus. For example, the inferior meatus is a passageway that passes beneath the inferior turbinate. Ducts, known as the nasolacrimal ducts, drain tears from the eyes into the nose through openings located within the inferior meatus. The middle meatus is a passageway that extends inferior to the middle turbinate. The middle meatus contains the semilunar hiatus, with openings or ostia leading into the maxillary, frontal, and anterior ethmoid sinuses. The superior meatus is located between the superior and medial turbinates.
Nasal Polyps:
Nasal polyps are benign masses that grow from the lining of the nose or paranasal sinuses. Nasal polyps often result from chronic allergic rhinitis or other chronic inflammation of the nasal mucosa. Nasal polyps are also common in children who suffer from cystic fibrosis. In cases where nasal polyps develop to a point where they obstruct normal drainage from the paranasal sinuses, they can cause sinusitis.
Sinusitis:
The term “sinusitis” refers generally to any inflammation or infection of the paranasal sinuses. Sinusitis can be caused by bacteria, viruses, fungi (molds), allergies or combinations thereof. It has been estimated that chronic sinusitis (e.g., lasting more than 3 months or so) results in 18 million to 22 million physician office visits per year in the United States.
Patients who suffer from sinusitis typically experience at least some of the following symptoms:
Proposed Mechanism of Sinus Pain & Diagnosis
The sinuses consist of a series of cavities connected by passageways, ultimately opening into the nasal cavity. As described previously, these passageways and cavities are formed by bone, but covered in mucosa. If the mucosa of one of these passageways becomes inflamed for any reason, the cavities which drain through that passageway can become blocked. This trapping of mucous can be periodic (resulting in episodes of pain) or chronic. Chronically blocked passageways are targets of infection. Ultimately, it is the dimensions of the bony passageways and thickness of the overlying mucosa and its chronicity that dictate the duration and severity of sinus symptoms. Thus, the primary target for sinus therapy is the passageway, with the primary goal to regain drainage. Often CT will not reveal these dimensional issues, especially when the patient is not currently experiencing severe symptoms. Therefore there exists a need to dynamically evaluate the sinus passageways under normal conditions, in response to challenging stimuli. As suggested herein, if it would be possible to assess sinus disease and its dynamic component, one might better target therapy for sinusitis and possibly be able to treat patients in a more focused and minimally invasive manner. Such focus on the passageway and the use of flexible instrumentation suggests an entirely new approach to sinus intervention: one utilizing flexible catheters and guidance tools, with passageway and cavity modifying devices capable of being delivered with minimal damage to the surrounding tissues.
Deviated Septum:
The intranasal septum is a cartilaginous anatomical structure that divides one side of the nose from the other. Normally, the septum is relatively straight. A deviated septum is a condition where the cartilage that forms the septum is abnormally curved or bent. A deviated nasal septum may develop as the nose grows or, in some cases, may result from trauma to the nose. A deviated septum can interfere with proper breathing or may obstruct normal drainage of nasal discharge, especially in patient's whose nasal turbinates are swollen or enlarged due to allergy, overuse of decongestant medications, etc., Such interference with drainage of the sinuses can predispose the patient to sinus infections.
A deviated nasal septum that interferes with proper function of the nose can be surgically corrected by a procedure known as septoplasty. In a typical septoplasty procedure, an endoscope is inserted into the nose and the surgeon makes an incision inside the nose, lifts up the lining of the septum, and removes and straightens the underlying bone and cartilage that is abnormally deviated. Such surgical septoplasty procedures can effectively straighten a deviated septum but, because the nasal cartilage has some memory, the septum may tend to resume its original deviated shape.
Reduction/Removal of Nasal Turbinates
Various surgical techniques, including endoscopic surgery, have been used for reduction and/or removal of the inferior turbinate in patient's whose inferior turbinate is chronically enlarged such that it is obstructing normal breathing and/or normal drainage from the paranasal sinuses. Typically, chronic enlargement of the inferior turbinates is the result of allergies or chronic inflammation. Enlargement of the inferior turbinate can be especially problematic in patient's who also suffer from a deviated septum that crowds or impinges upon the soft tissue of the turbinate. Thus, a septoplasty to straighten the deviated septum is sometimes performed concurrently with a reduction of the inferior turbinates.
Sinus Tumors
Most polyps are benign, but one form of a nasal polyp, known as an inverting papilloma, can develop into a malignancy. Unlike most benign polyps, which typically occur on both sides of the nose, an inverting papilloma is usually found on just one side. Thus, in cases where a unilateral polyp is observed, it is usually biopsied to determine if it is malignant. If an inverting papilloma is detected before it becomes malignant and is removed completely, it will typically not recur. However, using the technology that has heretofore been available, it has sometimes been difficult to determine if the papilloma has been entirely removed unless and until regrowth of the polyp is observed on long term post-surgical follow-up.
Various benign sinus tumors have also been known to occur, but are relatively rare. The most common form of malignant sinus tumor is squamous cell carcinoma. Even with surgery and radiation treatment, squamous cell carcinoma of the paranasal sinus is associated with a relatively poor prognosis. Other types of malignant tumors that invade the paranasal sinuses include adenocarcinoma and, more rarely, lymphoma and even more rarely, melanoma.
Facial Fractures
The most common cause of fractures of the facial bones is auto accidents, but facial fractures are also frequently caused by sports injuries, industrial accidents, falls, assaults and gunshot wounds. Some facial fractures involve bones that are accessible from inside the nasal cavities or paranasal sinuses. Notably, the nose is the most commonly injured facial structure due to its prominent position on the face. Thus, fractures of the nasal bone (with or without resultant deviated septum) are not uncommon. Other facial fractures such as fractures of the orbital floor and/or the ethmoid or frontal sinuses are also accessible from inside the nose or sinuses. A common type of orbital floor fracture is a “blowout” fracture that typically results from blunt trauma to the eye where the force is transmitted downwardly causing the relatively thin bone that forms the floor of the orbit to fracture downwardly. This can cause the periorbital tissues to herniate into the maxillary sinus and sometimes can also create a “trap door” of bone that extends downwardly into the maxillary sinus.
Endoscopic Sinus Surgery and Other Current Procedures
Functional Endoscopic Sinus Surgery
The most common corrective surgery for chronic sinusitis is functional endoscopic sinus surgery (FESS). In FESS, an endoscope is inserted into the nose and, under visualization through the endoscope, the surgeon may remove diseased or hypertrophic tissue or bone and may enlarge the ostia of the sinuses to restore normal drainage of the sinuses. FESS procedures can be effective in the treatment of sinusitis and for the removal of tumors, polyps and other aberrant growths from the nose. Other endoscopic intranasal procedures have been used to remove pituitary tumors, to treat Graves disease (i.e., a complication of hyperthyroidism which results in protrusion of the eyes) and surgical repair of rare conditions wherein cerebrospinal fluid leaks into the nose (i.e., cerebrospinal fluid rhinorrhea).
Surgery to reduce the size of the inferior turbinates can be accomplished with endoscopic visualization (with magnification where desired) and is typically performed with the patient under general anesthesia. An incision is typically made in the mucosa that lines the turbinate to expose the underlying bone. Some quantity of the underlying bone may then be removed. If selective removal of some of the mucosa or soft tissue is also desired, such soft tissue can be debulked or removed through by traditional surgical cutting or by the use of other tissue ablation or debulking apparatus such as microdebriders or lasers. Less frequently, chronically enlarged inferior turbinates have been treated by cryotherapy. It is typically desirable to remove only as much tissue as necessary to restore normal breathing and drainage, as removal of too much tissue from the turbinates can impair the ability of the turbinates to perform their physiological functions of warming and humidifying inspired air and conserving warmth and moisture from expired air. Complications associated with inferior turbinate surgery include bleeding, crusting, dryness, and scarring.
In some patients, the middle turbinate is enlarged due to the presence of an invading air cell (concha bullosa), or the middle turbinate may be malformed (paradoxically bent). Severe ethmoid sinusitis or nasal polyps can also result in enlargement or malformation of the middle turbinates. Since a substantial amount of drainage from the sinuses passes through the middle meatus (i.e., the passage that runs alongside middle turbinate) any enlargement or malformation of the middle turbinate can contribute to sinus problems and require surgical correction. Thus, in some FESS procedures carried out to treat sinusitis, the middle meatus is cleared (e.g., the polyps or hypertorophic tissue are removed) thereby improving sinus drainage. However, the middle turbinate can include some of the olfactory nerve endings that contribute to the patient's sense of smell. For this reason, any reduction of the middle turbinate is typically performed in a very conservative manner with care being taken to preserve as much tissue as possible. In patients who suffer from concha bullosa, this may involve removing the bone on one side of an invading air sac. In the cases where the middle turbinate is malformed, just the offending portion(s) of the turbinate may be removed.
Extended Endoscopic Frontal Sinus Surgery
Because of its narrow anatomical configuration, inflammation of the frontal sinuses can be particularly persistent, even after surgery and/or medical therapy has resolved the inflammation in the other paranasal sinuses. In cases of persistent inflammation of the frontal sinuses, a surgery known as a trans-septal frontal sinusotomy, or modified Lothrop procedure, is sometimes performed. In this procedure, the surgeon removes a portion of the nasal septum and the bony partition between the sinuses to form one large common drainage channel for draining the frontal sinuses into the nose. This complicated procedure, as well as some other ear, nose and throat surgical procedures, can carry a risk of penetrating the cranial vault and causing leakage of cerebrospinal fluid (CSF). Also, some sinus surgeries as well as other ear, nose and throat procedures are performed close to the optic nerves, the eyes, and the brain and can cause damage to those structures. To minimize the potential for such untoward complications or damage, image-guided surgery systems have been used to perform some complex head and neck procedures. In image guided surgery, integrated anatomical information is supplied through CT-scan images or other anatomical mapping data taken before the operation. Data from a preoperative CT scan or other anatomical mapping procedure is downloaded into a computer and special sensors known as localizers are attached to the surgical instruments. Thus, using the computer, the surgeon can ascertain, in three dimensions, the precise position of each localizer-equipped surgical instrument at any given point in time. This information, coupled with the visual observations made through the standard endoscope, can help the surgeon to carefully position the surgical instruments to avoid creating CSF leaks and to avoid causing damage to nerves or other critical structures.
Shortcomings of FESS
Although FESS continues to be the gold standard therapy for severe sinuses, it has several shortfalls. Often patients complain of the post-operative pain and bleeding associated with the procedure, and a significant subset of patients remain symptomatic even after multiple surgeries. Since FESS is considered an option only for the most severe cases (those showing abnormalities under CT scan), a large population of patients exist that can neither tolerate the prescribed medications nor be considered candidates for surgery. Further, because the methodologies to assess sinus disease are primarily static measurements (CT, MRI), patients whose symptoms are episodic are often simply offered drug therapy when in fact underlying mechanical factors may play a significant role. To date, there is no mechanical therapy offered for these patients, and even though they may fail pharmaceutical therapies, no other course of action is indicated. This leaves a large population of patients in need of relief, unwilling or afraid to take steroids, but not sick enough to qualify for surgery.
One of the reasons why FESS and sinus surgery is so bloody and painful relates to the fact that straight instrumentation with rigid shafts are used. Due to the fact that the sinuses are so close to the brain and other important structures, physicians have developed techniques using straight tools and image guidance to reduce the likelihood of penetrating into unwanted areas. In an effort to target deep areas of the anatomy, this reliance on straight instrumentation has resulted in the need to resect and remove or otherwise manipulate any anatomical structures that may lie in the path of the instruments, regardless of whether those anatomical structures are part of the pathology. With the advances in catheter based technology and imaging developed for the cardiovascular system, there exists a significant opportunity to reduce the morbidity of sinus interventional through the use of flexible instrumentation and guidance.
If flexible tools could be developed such that sinus intervention may be able to be carried out with even less bleeding and post-operative pain, these procedures may be applicable to a larger group of patients. Further, as described here, flexible instrumentation may allow the application of new diagnostic and therapeutic modalities that have never before been possible.
Laser or Radiofrequency Turbinate Reduction Soft Tissue Only)
In cases where it is not necessary to revise the bone that underlies the turbinate, the surgeon may elect to perform a laser or radiofrequency procedure designed to create a coagulative lesion in (or on) the turbinate, which in turn causes the soft tissue of the turbinate to shrink. Also, in some cases, a plasma generator wand may be used create high energy plasma adjacent to the turbinate to cause a reduction in the size of the turbinate.
One example of a radio frequency procedure that may be used to shrink enlarged inferior turbinates is radiofrequency volumetric tissue reduction (RFVTR) using the Somnoplasty® system (Somnus Medical Technologies, Sunnyvale, Calif.). The Somnoplasty® system includes a radio frequency generator attached to a probe. The probe is inserted through the mucosa into the underlying soft tissue of the turbinate, usually under direct visualization. Radiofrequency energy is then delivered to heat the submucosal tissue around the probe, thereby creating a submucosal coagulative lesion while allowing the mucosa to remain in tact. As the coagulative lesion heals, the submucosal tissue shrinks thereby reducing the overall size of the turbinate. Radiofrequency volumetric tissue reduction (RFVTR) can be performed as an office procedure with local anesthesia.
Many of the above-described procedures and techniques may be adaptable to minimally invasive approaches and/or the use of flexible instrumentation. There exists a need in the art for the development of such minimally invasive procedures and techniques as well as instrumentation (e.g., flexible instruments or catheters) useable to perform such procedures and techniques.
The skull contains a series of cavities known as paranasal sinuses that are connected by passageways. The paranasal sinuses are lined with mucous-producing mucosal tissue and ultimately open into the nasal cavity. Normally, mucous produced by the mucosal tissue slowly drains out of each sinus through an opening known as an ostium. If the mucosal tissue of one of these passageways becomes inflamed for any reason, the cavities which drain through that passageway can become blocked. This blockage can be periodic (resulting in episodes of pain) or chronic. This interference with drainage of mucous (e.g., occlusion of a sinus ostium) can result in mucosal congestion within the paranasal sinuses. Chronic mucosal congestion of the sinuses can cause damage to the epithelium that lines the sinus with subsequent decreased oxygen tension and microbial growth (e.g., a sinus infection).
The term “sinusitis” refers generally to any inflammation or infection of the paranasal sinuses caused by bacteria, viruses, fungi (molds), allergies or combinations thereof. It has been estimated that chronic sinusitis (e.g., lasting more than 3 months or so) results in 18 million to 22 million physician office visits per year in the United States. Patients who suffer from sinusitis typically experience at least some of the following symptoms: headaches or facial pain; nasal congestion or post-nasal drainage; difficulty breathing through one or both nostrils; bad breath; and/or pain in the upper teeth.
One of the ways to treat sinusitis is by restoring the lost mucous flow. The initial therapy is typically drug therapy using anti-inflammatory agents to reduce the inflammation and antibiotics to treat the infection. A large number of patients do not respond to drug therapy. Currently, the gold standard for patients with chronic sinusitis that do not respond to drug therapy is a corrective surgery called Functional Endoscopic Sinus Surgery (FESS).
As indicated above, FESS does have several shortcomings. For example, FESS can cause significant post-operative pain. Also, some FESS procedures are associated with significant postoperative bleeding and, as a result, nasal packing is frequently placed in the patient's nose for some period of time following the surgery. Such nasal packing can be uncomfortable and can interfere with normal breathing, eating, drinking etc. Also, some patients remain symptomatic even after multiple FESS surgeries. Additionally, some FESS procedures are associated with risks of iatrogenic orbital, intracranial and sinonasal injury. Many otolaryngologists consider FESS an option only for patients who suffer from severe sinus disease (e.g., those showing significant abnormalities under CT scan). Thus, patients with less severe disease may not be considered candidates for FESS
In work done in connection with the present invention, new devices, systems and techniques are being developed for the treatment of sinusitis and other disorders of the ear, nose, throat and paranasal sinuses. For example, various catheters, guidewires and other devices useable to perform minimally invasive, minimally traumatic ear, nose and throat surgery have been described in U.S. patent application Ser. No. 10/829,917 entitled “Devices, Systems and Methods for Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose and/or Throat,” issued as U.S. Pat. No. 7,654,997 on Feb. 2, 2010, Ser. No. 10/912,578 entitled “Implantable Device and Methods for Delivering Drugs and Other Substances to Treat Sinusitis and Other Disorders,” issued as U.S. Pat. No. 7,361,168 on Apr. 22, 2008, Ser. No. 10/944,270 entitled “Apparatus and Methods for Dilating and Modifying Ostia of Paranasal Sinuses and Other Intranasal or Paranasal Structures,” published as U.S. Patent Publication No. 2006/0004323 on Jan. 5, 2006, now abandoned, Ser. No. 11/037,548 entitled “Devices, Systems and Methods For Treating Disorders of the Ear, Nose and Throat”, issued as U.S. Pat. No. 7,462,175 on Dec. 9, 2009, and Ser. No. 11/116,118 entitled “Methods and Devices For Performing Procedures Within the Ear, Nose, Throat and Paranasal Sinuses,” issued as U.S. Pat. No. 7,720,521 on May 18, 2010. Each of these applications is hereby incorporated herein, in its entirety, by reference thereto. Many of these new devices, systems and techniques are useable in conjunction with endoscopic, radiographic and/or electronic assistance to facilitate precise positioning and movement of catheters, guidewires and other devices within the ear, nose, throat and paranasal sinuses and to avoid undesirable trauma or damage to critical anatomical structures such as the eyes, facial nerves and brain.
For example, in one new procedure (referred to in this patent application as a “Flexible Transnasal Sinus Intervention” or FTSI), a dilatation catheter (e.g., a balloon catheter or other type of dilator) is advanced through the nose to a position within the ostium of a paranasal sinus or other location, without requiring removal or surgical alteration of other intranasal anatomical structures. The dilatation catheter is then used to dilate the ostium or other anatomical structures to facilitate natural drainage from the sinus cavity. In some cases, a tubular guide may be initially inserted through the nose and advanced to a position near the sinus ostium and a guidewire may then be advanced through the tubular guide and into the affected paranasal sinus. The dilatation catheter may then be advanced over the guidewire and through the tubular guide to a position where its dilator (e.g., balloon) is positioned within the sinus ostium. The dilator (e.g., balloon) is then expanded causing the ostium to dilate. In some cases, such dilatation of the ostium may fracture, move or remodel bony structures that surround or are adjacent to the ostium. Optionally, in some procedures, irrigation solution and/or therapeutic agents may be infused through a lumen of the dilatation catheter and/or other working devices (e.g., guidewires, catheters, cannula, tubes, dilators, balloons, substance injectors, needles, penetrators, cutters, debriders, microdebriders, hemostatic devices, cautery devices, cryosurgical devices, heaters, coolers, scopes, endoscopes, light guides, phototherapy devices, drills, rasps, saws, etc.) may be advanced through the tubular guide and/or over the guidewire to deliver other therapy to the sinus or adjacent tissues during the same procedure in which the FTSI is carried out. It is to be understood that, in FTSI procedures, structures and passageways other than sinus ostia may be dilated using the tools described above, tissue may be resected or ablated, bone may be restructured, drugs or drug delivery systems may be deployed, etc., as described in the documents incorporated herein by reference. Thus, for the purposes of this application the term FTSI will be generally used to refer broadly to all of those procedures, not just dilation of sinus ostia.
In FTSI procedures that include positioning of a guidewire into a paranasal sinus, the placement of the guidewire is typically confirmed by visualizing the procedure under fluoroscopy or other x-ray visualization technique, for example. Appropriate positioning of the tubular guide at the position near the sinus ostium may also be confirmed via fluoroscopy. In order to reduce the radiation exposure to the patient undergoing the procedure, and particularly to the surgeon and other personnel that carry out many of these types of procedures, there is a need for methods and devices that eliminate or reduce the need to use fluoroscopic visualization during such procedures.
In general, the present invention provides methods, devices and systems for diagnosing and/or treating sinusitis or other conditions of the ear, nose or throat.
In accordance with the present invention, there are provided methods wherein one or more flexible catheters or other flexible elongate devices as described herein are inserted in to the nose, nasopharynx, paranasal sinus, middle ear or associated anatomical passageways to perform an interventional or surgical procedure. Examples of procedures that may be performed using these flexible catheters or other flexible elongate devices include but are not limited to: delivering contrast medium; delivering a therapeutically effective amount of a therapeutic substance; implanting a stent, tissue remodeling device, substance delivery implant or other therapeutic apparatus; cutting, ablating, debulking, cauterizing, heating, freezing, lasing, dilating or otherwise modifying tissue such as nasal polyps, aberrant or enlarged tissue, abnormal tissue, etc.; grafting or implanting cells or tissue; reducing, setting, screwing, applying adhesive to, affixing, decompressing or otherwise treating a fracture; delivering a gene or gene therapy preparation; cutting, ablating, debulking, cauterizing, heating, freezing, lasing, forming an osteotomy or trephination in or otherwise modifying bony or cartilaginous tissue within paranasal sinus or elsewhere within the nose; remodeling or changing the shape, size or configuration of a sinus ostium or other anatomical structure that affects drainage from one or more paranasal sinuses; removing puss or aberrant matter from the paranasal sinus or elsewhere within the nose; scraping or otherwise removing cells that line the interior of a paranasal sinus; removing all or a portion of a tumor; removing a polyp; delivering histamine, an allergen or another substance that causes secretion of mucous by tissues within a paranasal sinus to permit assessment of drainage from the sinus; implanting a cochlear implant or indwelling hearing aid or amplification device, etc.
Further in accordance with the invention, there are provided methods for diagnosing and assessing sinus conditions, including methods for delivering contrast media into cavities, assessing mucosal flow, assessing passageway resistance and cilliary function, exposing certain regions to antigen challenge, etc.
Still further in accordance with the invention, there are provided novel devices for performing some or all of the procedures described herein.
A method for visually confirming the positioning of a distal end portion of a device placed within a patient is provided to include: inserting a distal end portion of an illuminating device internally into a patient, emitting light from the distal end portion of the illuminating device; observing transillumination resulting from the light emitted from the distal end portion of the illuminating device that occurs on an external surface of the patient; and correlating the location of the observed transillumination on the external surface of the patient with an internal location of the patient that underlies the location of observed transillumination, to confirm positioning of the distal end portion of the illuminating device.
In at least one embodiment, the observation is performed by direct line of sight human observation, without the need for fluoroscopy. In at least one embodiment, the observation is performed by direct line of sight human observation, without the need for any visualization equipment. In at least one embodiment, the illuminating device comprises a guidewire. In at least one embodiment, the illuminating device comprises an ostium seeker device. In at least one embodiment, the illuminating device comprises a sinus suction instrument. In at least one embodiment, the illuminating device comprises an integrated wire dilatation catheter, wherein an integrated illuminating guidewire extends distally of a distal end of a dilatation catheter. In at least one embodiment, the distal end portion of the illuminating guidewire is inserted into a sinus passageway of the patient. In at least one embodiment, the distal end portion of the illuminating guidewire is inserted through an ostium opening to a sinus of the patient, and the distal end portion is advanced into the sinus. In at least one embodiment, the distal end portion of the illuminating guidewire is initially inserted through a nostril of the patient and then advanced into a sinus. In at least one embodiment, a scope is inserted through the nostril of the patient, wherein the guidewire is inserted adjacent the scope, and visualization of the advancement of the distal end portion of the guide wire is performed via the scope as the distal end portion is advanced toward an ostium of the sinus. In at least one embodiment, transillumination is observed when a light emitting portion of the distal end portion is located in the sinus of the patient.
If observation of transillumination and correlation reveals that the distal end portion of the illumination device has been misrouted to a location other than a target location, distal end portion of the device can be retracted and re-routed to the target location, which can be confirmed by observing transillumination and correlating.
In observing transillumination, the motion of the transillumination spot resulting from the light emitted from the distal end portion of the illuminating device can be observed and tracked or followed visually, as the distal end portion is moved relative to the patient, and this can be one way of confirming that the transillumination spot in motion correlates to a position of the distal end portion. This technique can be particularly useful when there are additional sources of transillumination, such as a light from a scope, for example.
Further, transillumination resulting from the light emitted from the distal end portion of the device can be distinguished from transillumination resulting from light emitted from a scope by identifying a transillumination spot that is at least one of brighter, smaller or more well-defined than other transillumination effects observed. Alternatively, the transillumination resulting from the light emitted from the distal end portion of the device can be distinguished from transillumination resulting from light emitted from a scope by turning off or down the light source to the scope.
In at least one embodiment, a sinus guide is inserted within the patient prior to inserting the device, and the distal end portion of the illuminating device is inserted through the sinus guide. In at least one embodiment, the illuminating device is preloaded in the guide, and the guide and preloaded illuminating device are inserted together into the patient. Advancement of the illuminating device relative to the guide can then be performed to extend a distal end portion of the illuminating device distally of a distal end of the guide.
A scope may be inserted within the patient, wherein the sinus guide is inserted adjacent the scope, and advancement of the sinus guide can be visualized via the scope.
In at least one embodiment, visualization of the advancement of the sinus guide is through use of the scope, up to a limit of adequate illumination by the scope. After that, the light emitted by the distal end portion of the illuminating device, having been advanced distally of a distal end of the sinus guide, extends the limit of adequate illumination of the scope, thereby extending a length of the adequate illumination of the scope. In at least one embodiment, the sinus guide can be further distally advanced under visualization by the scope as facilitated by the extended length of the adequate illumination. In at least one embodiment, visualization of the advancement of the illuminating device distally of the sinus guide can be performed via the scope, as facilitated by the light emitted from the distal end portion of the device. In at least one embodiment, the scope is inserted into a nostril of the patient, and the sinus guide is inserted adjacent the scope. In at least one embodiment, the scope and sinus guide are advanced into a sinus passageway of the patient. In at least one embodiment, the sinus guide is further advanced toward an ostium of a sinus, and the advancement of the sinus guide is visually observed via the scope. In at least one embodiment, the scope is inserted into a nostril of the patient, and the sinus guide is inserted adjacent the scope. The advancement of the sinus guide into a sinus passageway is visualized via the scope until a distal end of the sinus guide has reached a distal limit of illumination emitted by the scope. In at least one embodiment, further advancement of the sinus guide toward an ostium of a sinus is visualized via the scope as facilitated by the extended length of adequate illumination provided by the illumination device. In at least one embodiment, the scope is inserted into a nostril of the patient, and the sinus guide is inserted adjacent the scope. The advancement of the sinus guide to place a distal end of the sinus guide adjacent an approach to an ostium of a sinus is visualized via the scope. In at least one embodiment, the distal end portion of the illuminating device is advanced further distally of a distal end of the sinus guide and distal of the limit of illumination of the scope to emit illumination, thereby extending a length of a space that is visualizable by the scope. In at least one embodiment, the distal end portion of the device is further advanced into and through the ostium, and visualization of the advancement of the distal end portion into the ostium is performed via the scope. In at least one embodiment the device comprises an illuminating guidewire, a working device is advanced over the guidewire to position a working end of the working device at a target location, and a surgical procedure is performed with the working device at the target location. The working device is removed from the patient after performing the surgical procedure. Optionally, an implant can be left at the target location.
A method of performing a minimally invasive surgical procedure is provided, including the steps of: inserting a distal end portion of an illuminating guidewire internally into a patient; emitting light from the distal end portion of the illuminating guidewire, wherein a proximal end portion is connected to a power source to enable the distal end portion to emit light; observing transillumination resulting from the light emitted from the distal end portion of the illuminating guidewire that occurs on an external surface of the patient; correlating the location of the observed transillumination on the external surface of the patient with an internal location of the patient that underlies the location of observed transillumination, to confirm positioning of the distal end portion of the illuminating guidewire; disconnecting the proximal end portion of the illuminating guidewire from the power source; advancing a working device over the guidewire so that a proximal end of the guidewire extends proximally from the working device; reconnecting the proximal end portion of the illuminating guidewire to the power source so that the distal end portion of the guidewire again emits light; positioning a working end of the working device at a target location; and performing a surgical procedure with the working device at the target location.
After performing the surgical procedure, the proximal end portion of the illuminating guidewire is disconnected from the power source; and the working device is removed from the patient and from the guidewire. Optionally, an implant can be left at the target location.
In at least one embodiment, a second working device is advanced over the guidewire after removing the first working device therefrom, so that a proximal end of the guidewire extends proximally from the second working device. Then the proximal end portion of the illuminating guidewire is reconnected to the power source so that the distal end portion of the guidewire again emits light. In at least one embodiment, the illuminating guidewire includes at least one illumination fiber extending from a proximal end of the guidewire to the distal end portion, and the power source is a light source. In at least one embodiment, the illuminating guidewire includes at least one laser fiber extending from a proximal end of the guidewire to the distal end portion, and the power source is a laser light source. In at least one embodiment, the illuminating guidewire includes a light emitting diode at the distal end portion and electrical wires extending through the guidewire, electrically connecting the light emitting diode to the power source, and wherein the power source is an electrical power source.
A method for diagnosing and/or treating sinusitis or another disorder affecting a nose, a sinus or other anatomical structure of the ear, nose or throat in a human or animal patient is provided, including the steps of: advancing an introducing device through the nose and to a position where the distal end of the introducing device is near an opening of a sinus; advancing a distal end portion of an illuminating device that emits light from the distal end portion thereof through the introducing device while a proximal end of the illuminating device is connected to a power source; and monitoring a position of the distal end portion of the illuminating device distally of the distal end of the introducing device, by observing transillumination on an external surface of the patient that results from the light emitted by the distal end portion. The light emitted can be a desired wavelength in the visible spectrum and/or infrared spectrum.
In at least one embodiment, the distal end portion of the illuminating device is advanced through the opening of the sinus; and placement of the distal end portion of the illuminating device in the sinus is confirmed by observing the transillumination resulting from the light emitted from the distal end portion of the illuminating device that occurs on the external surface of the patient, and correlating the location of the observed transillumination on the external surface of the patient with an internal location of the patient that underlies the location of observed transillumination. In at least one embodiment, the external surface on which the transillumination is observed is on the face of the patient. In at least one embodiment, the external surface on which the transillumination is observed is on the palate of the patient. In at least one embodiment the illuminating device comprises an illuminating guidewire, and a working device is provided that is positionable in an operative location and useable to perform a diagnostic or therapeutic procedure there. The proximal end of the illuminating guidewire is disconnected from the power source, while maintaining the distal end portion of the illuminating guidewire in its current position, and the working device is advanced over the guidewire so that a proximal end of the guidewire extends proximally from the working device. The proximal end of the illuminating guidewire is then reconnected to the power source so that the distal end portion of the guidewire again emits light. The working device is further advanced to position a working end of the working device at the operative location, and a diagnostic or therapeutic procedure is performed with the working device at the operative location. In at least one embodiment, the operative location is the opening to the Sinus.
An illuminating guidewire device is provided, including: a flexible distal end portion; a relatively less flexible proximal end portion; at least one light emitting element in the distal end portion; and at least one structure extending from a proximal end of the device through the proximal end portion and at least part of the distal end portion to connect the at least one light emitting element with a power source located proximally of the device.
In at least one embodiment, the at least one light emitting element comprises a distal end of at least one illumination fiber, and the at least one structure comprises the at least one illumination fiber running proximally of the distal end of the fiber to the proximal end of the device. In at least one embodiment, the power source is a light source. In at least one embodiment, the at least one light emitting element of the illuminating guidewire comprises a distal end of at least one laser fiber, and the at least one structure comprises the at least one laser fiber running proximally from the distal end of the fiber to the proximal end of said device. In at least one embodiment, the power source is a laser light source. In at least one embodiment, the at least one light emitting element comprises a light emitting diode, and the at least one structure comprises at least one electrical wire electrically connected to the light emitting diode and extending proximally of the light emitting diode to the proximal end of the device. In at least one embodiment, the power source is an electrical power source. In at least one embodiment, the distal end portion of the guidewire has an outside diameter configured and dimensioned to pass through an ostium of a sinus. In at least one embodiment, the distal end portion of the guidewire has an outside diameter less than about 0.038 inches. In at least one embodiment, the distal end portion of the guidewire has an outside diameter of about 0.035″±0.005″. In at least one embodiment, the illuminating guidewire has a maximum outside diameter of less than about 0.038 inches. In at least one embodiment, the illuminating guidewire has a maximum outside diameter of less than about 0.035 inches. In at least one embodiment, the illuminating guidewire has a maximum outside diameter of about 0.035″±0.005″. In at least one embodiment, the distal end portion of the device comprises a flexible coil. In at least one embodiment, the distal end portion further comprises a core support extending internally of the coil. In at least one embodiment, the core support is fixed to the coil. In at least one embodiment, a core support extending within the distal and proximal end portions of the device. In at least one embodiment, the core support extends within substantially the full length of the distal and proximal end portions. In at least one embodiment, the distal end portion of the device includes a bend, such that a proximal part of the distal end portion is substantially aligned with a longitudinal axis of the device, and a distal part of the distal end portion is angled with respect to the longitudinal axis. In at least one embodiment, the distal end of at least one illumination fiber is configured to emit light from a distal tip of the distal end portion of the device. The distal tip can be designed to either focus or distribute the light to achieve maximum transillumination. The distal tip can include a lens, prism or diffracting element. In at least one embodiment, the distal end of at least one illumination fiber is positioned proximally of a distal tip of the distal end portion of the device. In at least one embodiment, a flexible distal portion of the distal end portion extends distally of the distal end of the at least one illumination fiber. In at least one embodiment, the distal end of at least one laser fiber is configured to emit light from a distal tip of the distal end portion of the device. In at least one embodiment, the distal end of at least one laser fiber is positioned proximally of a distal tip of the distal end portion of the device. In at least one embodiment, a flexible distal portion of the distal end portion extends distally of the distal end of at least one illumination fiber. In at least one embodiment, a light emitting diode is mounted at a distal tip of the distal end portion of the device. In at least one embodiment, a light emitting diode is positioned proximally of a distal tip of the distal end portion of the device. In at least one embodiment, a flexible distal portion of the distal end portion extends distally of the light emitting diode. In at least one embodiment, an electrical power source is removably, electrically connected to at least one structure to provide electrical power to at least one light emitting element. In at least one embodiment, at least one light conducting tube delivers light from a proximal end portion of the device to a distal and of the tube, where it is emitted. In at least one embodiment, each light conducting tube is sealed in a proximal end of the device. In at least one embodiment, each light emitting element is sealed at a distal tip of the device. In at least one embodiment, a quick release connector is mounted over at least part of the proximal end portion of the guidewire. The quick release connector is adapted to be connected to a power source and to quickly connect to and release from the proximal end portion of the guidewire. In at least one embodiment, the quick release connector is optically coupled with a light source. In at least one embodiment, the proximal end portion of the quick release connector is adapted to connect with a light source. In at least one embodiment, the proximal end portion of the quick release connector comprises an ACMI light post. In at least one embodiment, the connector is rotatable with respect to a light channel extending from a light source, when the connector is connected to the light channel. In at least one embodiment, the light cable comprises a fluid filled light cable. In at least one embodiment, a distal end portion of the connector comprises an opening configured to slidably receive the proximal end portion of the guidewire device; and a quick release locking mechanism is configured to fix the proximal end portion received in the connector. In at least one embodiment, the quick release locking mechanism is movable between an unlocked configuration in which the proximal end portion can be slid from the connector to disconnect therefrom, and a locked configuration that maintains the proximal end portion in connection with the connector. In at least one embodiment, the quick release locking mechanism is biased toward the locked configuration. In at least one embodiment, a radiopaque marker is provided on the distal end portion of the guidewire. In at least one embodiment, an electromagnetic coil is provided at the distal end portion of the guidewire. Alternatively, a magnet, radiofrequency emitter or ultrasound crystal can be provided at the distal end portion of the guidewire.
An illuminating device is provided, including a distal end portion having an outside diameter configured and dimensioned to pass through an ostium of a sinus, at least one light emitting element in the distal end portion, and at least one structure extending from a proximal end of the device through the proximal end portion and at least part of the distal end portion to connect the at least one light emitting element with a power source.
In at least one embodiment, the illuminating device comprises an illuminating guidewire. In at least one embodiment, the illuminating device comprises an ostium seeker device, and the distal end portion is rigid or malleable. In at least one embodiment, the illuminating device comprises an ostium seeker device, and the distal end portion comprises a ball tip at a distal end thereof. In at least one embodiment, the illuminating device comprises a sinus suction instrument, and the distal end portion further comprises a suction lumen configured and adapted to apply suction therethrough. In at least one embodiment, the illuminating device comprises an integrated wire dilatation catheter, wherein an integrated illuminating guidewire extends distally of a distal end of a dilatation catheter of the device.
An illuminating guidewire device is provided including: a guidewire including an elongated main body having a flexible distal end portion and a relatively less flexible proximal end portion; at least one light conducting channel extending the length of the elongated body, and configured and dimensioned to deliver light from a proximal end of the guidewire to a distal end of the guidewire and to emit light from the distal end of the guidewire.
In at least one embodiment, the at least one light conducting channel comprises at least one illumination fiber. In at least one embodiment, the at least one light conducting channel comprises at least two illumination fibers. In at least one embodiment, the illumination fibers are formed of plastic. In at least one embodiment, the at least one illumination fiber is formed of glass. In at least one embodiment, the at least one light conducting channel comprises at least one laser fiber. In at least one embodiment, a quick release connector is mounted over at least part of the proximal end portion of the elongated body, and is adapted to be connected to a light channel extending from a light source; and to quickly connect to and release from the proximal end portion of the elongated body. In at least one embodiment, the quick release connector is optically coupled with the light source. In at least one embodiment, a proximal end portion of the connector comprises a tapering light channel configured to adapt a relatively larger inside diameter of the light channel to a relatively smaller diameter of the proximal end of the elongated body. In at least one embodiment, a proximal end portion of the quick release connector is adapted to connect with a light source. In at least one embodiment, the proximal end portion of the quick release connector includes an ACMI light post. In at least one embodiment, the connector is rotatable with respect to the light channel extending from the light source, when the connector is connected to the light channel. In at least one embodiment, the distal end portion of the connector comprises an opening configured to slidably receive the proximal end portion of the elongated body, and a quick release locking mechanism is configured to fix the proximal end portion received in the connector. In at least one embodiment, the quick release locking mechanism, in a locked configuration, maintains a proximal end of the elongated body in alignment with a distal end of the tapering light channel of the connector. In at least one embodiment, the quick release locking mechanism is movable between an unlocked configuration in which the proximal end portion can be slid from the connector to disconnect therefrom, and a locked configuration that maintains the proximal end portion in connection with the connector. In at least one embodiment, a core support extends at least within the distal end portion of the elongated body of the guidewire. In at least one embodiment, the core support further extends within the proximal end portion.
An illuminating guide wire device is provided, including: a guidewire having an elongated main body with a flexible distal end portion and a relatively less flexible proximal end portion; a light emitting diode mounted in the distal end portion and configured to emit light from a distal tip of the distal end portion; and at least one electrical wire extending the length of the elongated body, being electrically connected to the light emitting diode, and extending proximally of a proximal end of the elongated body.
In at least one embodiment, the illuminating guidewire device includes at least two such electrical wires. In at least one embodiment, a core support extends at least within the distal end portion of the elongated body. In at least one embodiment, the core support further extends within the proximal end portion. In at least one embodiment, a radiopaque marker is provided on the distal end portion. In at least one embodiment, an electromagnetic coil is provided on the distal end portion.
An illuminating guidewire device is provided, including: a guidewire having a flexible distal end portion, a relatively less flexible proximal end portion, and a transparent portion interconnecting the distal and proximal end portions; a least one light emitting element mounted in the guidewire and configured to emit light through the transparent portion; and at least one structure extending from a proximal end of the device through the proximal end portion and connecting with the at least one light emitting element.
In at least one embodiment, the transparent portion comprises a clear tube. In at least one embodiment, the clear tube includes cut out windows therein. In at least one embodiment, the transparent portion comprises a plurality of struts interconnecting the proximal and distal end portions of the guidewire. In at least one embodiment, a deflector is mounted distally of the at least one light emitting element in the transparent portion. In at least one embodiment, a quick release connector is mounted over at least part of the proximal end portion, and is adapted to be connected to a light channel extending from a light source, and to quickly connect to and release from the proximal end portion of the guidewire. In at least one embodiment, a core support extends at least within the distal end portion. In at least one embodiment, the core support further extends within the proximal end portion.
A quick release connector for use with an illuminating guidewire is provided to include: a main body having a proximal end portion and a distal end portion; a channel in the distal end portion and opening to a distal end of the main body, wherein the channel is configured and dimensioned to slidably receive a proximal end portion of the illuminating guidewire; and a quick release locking mechanism configured to assume a locked position and an unlocked position, wherein when in the locked position, the quick release locking mechanism fixes the proximal end portion of the illuminating guide wire in the channel.
In at least one embodiment, the quick release locking mechanism is biased to the locked position. In at least one embodiment, upon inserting the proximal end portion of the illuminating guidewire into the channel, the proximal end portion contacts portions of the quick release locking mechanism, driving the portions apart to allow the proximal end portion to be slid into the channel. In at least one embodiment, the quick release locking mechanism comprises a locking arm that extends into the channel and a portion that extends out of the housing, wherein the portion extending out of the housing is manually retractable to move the locking arm from the locked position to the unlocked position. In at least one embodiment, the quick release locking mechanism includes at least two locking arms provided circumferentially about the distal end portion of the main body of the connector. In at least one embodiment, the quick release locking mechanism comprises a pin vise. In at least one embodiment, the proximal end portion of the connector is adapted to be connected to a light channel extending from a light source. In at least one embodiment, the proximal end portion of the main body is optically coupled with a light source. In at least one embodiment, the proximal end portion of the main body includes a tapering light channel configured to adapt a relatively larger inside diameter of a light channel to a relatively smaller diameter of the proximal end of the illuminating guidewire. In at least one embodiment, the proximal end portion of the main body comprises an ACMI light post. In at least one embodiment, the quick release connector is rotatable with respect to a light channel extending from a light source, when the connector is connected to the light channel.
These and other advantages and features of the invention will become apparent to those persons skilled in the art upon reading the details of the devices, methods and systems as more fully described below. Further aspects, details and embodiments of the present invention will be understood by those of skill in the art upon reading the following detailed description of the invention and the accompanying drawings.
1 is a cross-sectional view through line 3C1-3C1 of
1, 3E11 and 3E111 are partial perspective views of still another embodiment of an occluder/suction device of the present invention showing various steps in a process by which the occluder/suction device is positioned within an anatomical passageway.
1, 3F11 and 3F111 show alternative constructions of the distal portion of the suction cannula of the occluder/suction device shown in
1 and 3L11 show partial longitudinal sectional views of another occluder/suction device of the present invention.
1 and 3M11 show partial perspective views of another occluder/suction device of the present invention positioned within an anatomical passageway.
1 is a partial perspective view of a balloon catheter having a stent positioned thereon being inserted into an occluded region within the nose, nasopharynx or paranasal sinus in accordance with the present invention.
11 shows the balloon catheter and stent of
111 shows the balloon catheter and stent of
1 shows the device of
1 is a cross-sectional view through line 5Q1-5Q1 of
1 shows an example of an optional modified shape of the balloon and stent of
11 shows another example of an optional modified shape of the balloon and stent of
1 is a cross-sectional view through line 5T1-5T1 of
1 and 5W11 show steps in a method for using the bone remodeling device of
1-5X111 are partial perspective views of alternative designs for bone remodeling devices of the present invention.
1-5Y11111 are perspective views of examples of substance delivering implant devices useable in the present invention.
The following detailed description and the accompanying drawings are intended to describe some, but not necessarily all, examples or embodiments of the invention only and does not limit the scope of the invention in any way.
Before the present devices and methods are described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a tube” includes a plurality of such tubes and reference to “the shaft” includes reference to one or more shafts and equivalents thereof known to those skilled in the art, and so forth.
The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
A number of the drawings in this patent application show anatomical structures of the ear, nose and throat. In general, these anatomical structures are labeled with the following reference letters:
Nasal Cavity NC
Nasopharynx NP
Superior Turbinate ST
Middle Turbinate MT
Inferior Turbinate IT
Frontal Sinus FS
Ethmoid Sinus ES
Sphenoid Sinus SS
Sphenoid Sinus Ostium SSO
Maxillary Sinus MS
The human nose has right and left nostrils or nares which lead into separate right and left nasal cavities. The right and left nasal cavities are separated by the intranasal septum, which is formed substantially of cartilage and bone. Posterior to the intranasal septum, the nasal cavities converge into a single nasopharyngeal cavity. The right and left Eustachian tubes (i.e., auditory tubes) extend from the middle ear on each side of the head to openings located on the lateral aspects of the nasopharynx. The nasopharynx extends inferiorly over the uvula and into the pharynx. As shown in
The present invention provides a comprehensive system of devices and associated methods for diagnosing and treating disorders of the ears, nose and throat in a less invasive fashion than current day approaches. Specifically, examples of which are described below, the invention provides devices that wholly or partially effect a fluid-tight seal of the operative field (e.g., the nasopharynx and/or one or more of the sinus cavities or regional ducts). This fluid-tight sealing of the operative field allows the cavities, ducts and passageways to be imaged using fluid/gas based agents in combination with various imaging modalities without the risk of aspiration or uncontrolled leakage of fluid from the operative field. Further, this fluid-tight sealing of the operative field permits the retention and collection of any blood or flushing fluids released during the procedure. Another aspect of the invention is a set of methods and devices useable to assess the static and dynamic nature of the paranasal sinuses and to provide for the guidance of specific therapies to particular sinuses or particular target regions (e.g., stenotic sinus ostia, infected tissues within sinuses, tumors, other target structures). Another aspect of the invention is the use of devices and methods which are designed for minimally invasive entry into the sinus passageways or regional ducts under image and/or endoscopic guidance to provide local therapy such as dilation, ablation, resection, injection, implantation, etc., to the region of concern. These devices and methods may be disposable or temporary in their application, or they may be implantable with on-going functionality (such as implantable drug delivery systems, cochlear implants, etc.). In a number of embodiments, the present invention utilizes flexible catheters and various working devices that are mounted on or delivered through elongate flexible members or catheters, to diagnose and treat a wide range of ear, nose and throat disorders, including nasal polyps, sinusitis, enlarged turbinates, deviated septum, tumors, infections, deformities, etc., The following pages describe a number of specific devices and methods that are useable in accordance with this invention. It is to be understood that any component, element, limitation, attribute or step described in relation to any particular device or method described herebelow, may be incorporated in or used with any other device or method of the present invention unless to do so would render the resultant device or method unusable for its intended purpose.
A. Occluders and Access Port Devices
Many of the procedures of the present invention require the insertion and positioning of one or more flexible catheters or other flexible elongate working devices (examples of which are shown in
It should be appreciated that in any embodiment of an anterior/posterior occluder & access device, such as the device 10 shown in
It is to be further appreciated that in embodiments that have anterior and posterior outlet openings 22, 24 (as shown in the example of
As shown in
B. Variations in Occluder Design and Suction Apparatus:
Although the above-described examples of occluder/access devices 10, 12, 300, 400 show occluders that are in nature of inflatable balloons, it will be appreciated that these occluders are not limited to balloons and may be of various other designs and types. Further, it is to be understood that various arrangements of access and/or suction tubing/port(s) may be used to facilitate in complete removal of blood, fluid or other debris from the areas adjacent to the occluder(s) and/or elsewhere in the operative field or optimal positioning of working devices within the operative field. In fact, certain occluder and/or suction-access tubing/port designs may be more desirable for certain procedures than others depending on a number of factors including the positioning of the patient's head during surgery, whether the patient will be under a general anesthetic, whether an endotracheal tube will be inserted, etc., In some cases, where a posterior occluder is positioned within the posterior choanae, nasopharynx or pharynx posterior to the nasal septum the completeness with which blood, other fluid or debris may be suctioned out of the area adjacent to that posterior occluder may depend on the shape and/or design of the occluder itself as well as the shape and location of the suction lumen(s) and port(s) through which the blood, fluid or debris is to be suctioned. Beyond optimized fluid control, the posterior occluder and/or associated access tubing may also serve as an essential guiding element for devices, and alternative shapes and trajectories may be particularly useful to access specific structures.
FIGS. 3C and 3C′ show another alternative wherein an occluder 460 had a depression or well 462 formed in its upper surface and a tube 464 is attached to the occluder 460, as shown. A lumen of the tube 464 is in communication with the area adjacent the floor of the well to facilitate suctioning of blood, fluid or debris that collects within the well. In embodiments where the occluder 460 comprises a balloon, the tube 464 may incorporate a suction lumen 468 and a balloon inflation/deflation lumen 470. A small curved (e.g., generally “U” shaped) suction tube 466 may be connected in a sealed connection to the distal end of suction lumen 468 and the interior of the well 462 such that blood, other fluid or debris may be suctioned from the well 462, through suction tube 466 and through suction lumen 468.
1-3E111 show yet another occluder/suction arrangement wherein the occluder 484 comprises an everting tubular member that is advanceable from a delivery/suction catheter 486. The everting tubular member comprises a frame 488 that is covered with a covering 500. Initially the everting tubular member is in a substantially cylindrical configuration within the lumen of the delivery/suction catheter 486. The frame may be a resilient or superelastic material that is biased to the everted shape shown in
111 show another embodiment wherein an occluder 510 is positioned on the end of a tube 512. The occluder 510 has an arched upper surface such that a generally “V” shaped annular collection space 518 is created in the region of the coaptation between the occluder 510 and the adjacent wall of the body lumen in which it is positioned (e.g., a nasal cavity, posterior choanae, nasopharynx, pharynx, etc.). A suction tube 516 extends from tube 512 into the annular collection space 518 and blood, other fluid or debris that collects in the annular collection space 518 may be suctioned through suction tube 516 and through a lumen of tube 512, thereby providing for maintenance of a substantially dry environment adjacent to the upper surface of the occluder 510. The occluder 510 may comprise a balloon or any other suitable occlusion member as described herein or known in the art. As shown in
1-3L11 show yet another occluder/tubing device 1000 comprising an outer tube 1002 and an inner tube 1004 disposed coaxially within the outer tube 1002. An outwardly bendable region 1006 is formed in the wall of the outer tube 1002 near its distal end. The distal end of the outer tube 1002 is affixed to the inner tube 1004. A passageway 1010 extends between the outer tube 1002 and inner tube 1004 and openings 1008 are formed in the wall of the outer tube 1002. In routine operation, this device 1000 is initially disposed in the configuration shown in
1 and 3M11 show another occluder/tubing device 1020 comprising an outer tube 1022 an inner tube 1024. The inner tube 1024 is advanceable out of the distal end of the outer tube 1022 and a distal portion of the inner tube 1024 expands as it emerges from the inner tube, thereby forming an occluder that occludes the body lumen or passageway in which it is positioned, as shown in
C. Working Devices for Delivering Substances or for Cutting, Ablating, Remodeling or Expanding Bone or Soft Tissue
The present invention provides a variety of apparatus that may be inserted into the nasal cavity, paranasal sinus, nasopharynx or middle ear to perform diagnostic or therapeutic procedures. These devices may be delivered through or incorporated into flexible catheters or flexible rod-like shafts. Such flexible construction allows these devices to be delivered and positioned to perform the desired diagnostic or therapeutic procedures with minimal trauma to other tissues, as can result from the insertion of rigid scopes and rigid instruments in accordance with the methodology of the prior art. It is within the scope of this approach that these devices may be partially flexible or have rigid portions and flexible portions to facilitate their control and guidance to the appropriate region. Further, they may be used in conjunction or combination with other standard rigid apparatus (scopes, etc.) during some part of the procedure, if desired.
Also, in some but not necessarily all procedures, these working devices (and/or the catheters used to deliver them) may be inserted through lumens of the occluder & access devices 10, 12, 300, 301, 400, 430, etc., as shown in
Optionally, any of the working devices and guide catheters described herein may be configured to receive or be advanced over a guidewire unless to do so would render the device inoperable for its intended purpose. Some of the specific examples described herein include guidewires, but it is to be appreciated that the use of guidewires and the incorporation of guidewire lumens is not limited to only the specific examples in which guidewires or guidewire lumens are shown. The guidewires used in this invention may be constructed and coated as is common in the art of cardiology. This may include the use of coils, tapered or non-tapered core wires, radiopaque tips and/or entire lengths, shaping ribbons, variations of stiffness, PTFE, silicone, hydrophilic coatings, polymer coatings, etc., For the scope of this inventions, these wires may possess dimensions of length between 5 and 75 cm and outer diameter between 0.005″ and 050″.
Also, some of the working devices shown in
As shown in the examples of
Some nonlimiting examples of antimicrobial agents that may be used in this invention include acyclovir, amantadine, aminoglycosides (e.g., amikacin, gentamicin and tobramycin), amoxicillin, amoxicillin/Clavulanate, amphotericin B, ampicillin, ampicillin/sulbactam, atovaquone, azithromycin, cefazolin, cefepime, cefotaxime, cefotetan, cefpodoxime, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cefuroxime axetil, cephalexin, chloramphenicol, clotrimazole, ciprofloxacin, clarithromycin, clindamycin, dapsone, dicloxacillin, doxycycline, erythromycin, fluconazole, foscamet, ganciclovir, atifloxacin, imipenem/cilastatin, isoniazid, itraconazole, ketoconazole, metronidazole, nafcillin, nafcillin, nystatin, penicillin, penicillin G, pentamidine, piperacillin/tazobactam, rifampin, quinupristin-dalfopristin, ticarcillin/clavulanate, trimethoprim/sulfamethoxazole, valacyclovir, vancomycin, mafenide, silver sulfadiazine, mupirocin, nystatin, triamcinolone/nystatin, clotrimazole/betamethasone, clotrimazole, ketoconazole, butoconazole, miconazole, tioconazole, detergent-like chemicals that disrupt or disable microbes (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, menfegol, and N-docasanol); chemicals that block microbial attachment to target cells and/or inhibits entry of infectious pathogens (e.g., sulphated and sulponated polymers such as PC-515 (carrageenan), Pro-2000, and Dextrin 2 Sulphate); antiretroviral agents (e.g., PMPA gel) that prevent retroviruses from replicating in the cells; genetically engineered or naturally occurring antibodies that combat pathogens such as anti-viral antibodies genetically engineered from plants known as “plantibodies;” agents which change the condition of the tissue to make it hostile to the pathogen (such as substances which alter mucosal pH (e.g., Buffer Gel and Acidform) or non-pathogenic or “friendly” bacteria or other microbes that cause the production of hydrogen peroxide or other substances that kill or inhibit the growth of pathogenic microbes (e.g., lactobacillus). As may be applied to any of the substances listed previously or below, these substances may be combined with any one or more drug-releasing devices or molecular constructs such as polymers, collagen, gels, implantable osmotic pump devices, etc., to permit their release over an extended period of time once deposited. Further, these substances may also be combined with any of the implantable structural devices described below (stents, expanders, etc.) to reduce Infection, encrustation, or encapsulation of the implant itself, or to allow the drug to be deposited in the optimal location mucosally, sub-mucosally or into the bone. Examples of Implantable substance delivery devices useable in this invention include those shown in FIGS. 5Y′-5Y11111 and described herebelow.
Additionally or alternatively, in some applications where it is desired to treat or prevent inflammation the substances delivered in this invention may include various steroids. For example, corticosteroids that have previously administered by intranasal administration may be used, such as beclomethasone (Vancenase® or Beconase®), flunisolide (Nasalideft fluticasone(Flonase®), triamcinolone (Nasacort®) and mometasone (Nasonex®). Also, other steroids that may be useable in the present invention include but are not limited, to aclometasone, desonide, hydrocortisone, betamethasone, clocortolone, desoximetasone, fluocinolone, flurandrenolide, mometasone, prednicarbate; amcinonide, desoximetasone, diflorasone, fluocinolone, fluocinonide, halcinonide, clobetasol, augmented betamethasone, diflorasone, halobetasol, prednasone, dexamethasone and methylprednisolone, Additionally or alternatively, in some applications, such as those where it is desired to treat or prevent an allergic or immune response, the substances delivered in this invention may include a) various cytokine inhibitors such as humanized anti-cytokine antibodies, anti-cytokine receptor antibodies, recombinant (new cell resulting from genetic recombination) antagonists, or soluble receptors; b) various leucotriene modifiers such as zaflrlukast, montelukast and zileuton; c) immunoglobulin E (IgE) inhibitors such as Omalizumab (an anti-IgE monoclonal antibody formerly called rhu Mab-E25) and secretory leukocyte protease inhibitor).
Additionally or alternatively, in some applications, such as those where it is desired to shrink mucosal tissue, cause decongestion or effect hemostasis, the substances delivered in this invention may include various vasoconstrictors for decongestant and or hemostatic purposes including but not limited to pseudoephedrine, xylometazoline, oxymetazoline, phenylephrine, epinephrine, etc.
Additionally or alternatively, in some applications, such as those where it is desired to facilitate the flow of mucous, the substances delivered in this invention may include various mucolytics or other agents that modify the viscosity or consistency of mucous or mucoid secretions, including but not limited to acetylcysteine (Mucomyst™, Mucosil™) and guaifenesin.
Additionally or alternatively, in some applications such as those where it is desired to prevent or deter histamine release, the substances delivered in this invention may include various mast cell stabilizers or drugs which prevent the release of histamine such as cromolyn (e.g., Nasal Chrom®) and nedocromil.
Additionally or alternatively, in some applications such as those where it is desired to prevent or inhibit the effect of histamine, the substances delivered in this invention may include various antihistamines such as azelastine (e.g., Astylin®), diphenhydramine, loratidine, etc.
Additionally or alternatively, in some embodiments such as those where it is desired to dissolve, degrade, cut, break or remodel bone or cartilage, the substances delivered in this invention may include substances that weaken or modify bone and/or cartilage to facilitate other procedures of this invention wherein bone or cartilage is remodeled, reshaped, broken or removed. One example of such an agent would be a calcium chelator such as EDTA that could be injected or delivered in a substance delivery implant next to a region of bone that is to be remodeled or modified. Another example would be a preparation consisting of or containing bone degrading cells such as osteoclasts. Other examples would include various enzymes of material that may soften or break down components of bone or cartilage such as collagenase (CGN), trypsin, trypsin/EDTA, hyaluronidase, and tosyllysylchloromethane (TLCM).
Additionally or alternatively, in some applications, the substances delivered in this invention may include other classes of substances that are used to treat rhinitis, nasal polyps, nasal inflammation, and other disorders of the ear, nose and throat including but not limited to anticolinergic agents that tend to dry up nasal secretions such as ipratropium (Atrovent Nasal®), as well as other agents not listed here.
Additionally or alternatively, in some applications such as those where it is desired to draw fluid from polyps or edematous tissue, the substances delivered in this invention may include locally or topically acting diuretics such as furosemide and/or hyperosmolar agents such as sodium chloride gel or other salt preparations that draw water from tissue or substances that directly or indirectly change the osmolar content of the mucous to cause more water to exit the tissue to shrink the polyps directly at their site.
Additionally or alternatively, in some applications such as those wherein it is desired to treat a tumor or cancerous lesion, the substances delivered in this invention may include antitumor agents (e.g., cancer chemotherapeutic agents, biological response modifiers, vascularization inhibitors, hormone receptor blockers, cryotherapeutic agents or other agents that destroy or inhibit neoplasia or tumorigenesis), such as alkylating agents or other agents which directly kill cancer cells by attacking their DNA (e.g., cyclophosphamide, isophosphamide), nitrosoureas or other agents which kill cancer cells by inhibiting changes necessary for cellular DNA repair (e.g., carmustine (BCNU) and lomustine (CCNU)), antimetabolites and other agents that block cancer cell growth by interfering with certain cell functions, usually DNA synthesis (e.g., 6-mercaptopurine and 5-fluorouracil (5FU), antitumor antibiotics and other compounds that act by binding or intercalating DNA and preventing RNA synthesis (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitomycin-C and bleomycin) plant (vinca) alkaloids and other anti-tumor agents derived from plants (e.g., vincristine and vinblastine), steroid hormones, hormone inhibitors, hormone receptor antagonists and other agents which affect the growth of hormone-responsive cancers (e.g., tamoxifen, herceptin, aromatase ingibitors such as aminoglutethamide and formestane, triazole inhibitors such as letrozole and anastrazole, steroidal inhibitors such as exemestane), antiangiogenic proteins, small molecules, gene therapies and/or other agents that inhibit angiogenesis or vascularization of tumors (e.g., meth-1, meth-2, thalidomide), bevacizumab (Avastin), squalamine, endostatin, angiostatin, Angiozyme, AE-941 (Neovastat), CC-5013 (Revimid), medi-522 (Vitaxin), 2-methoxyestradiol (2ME2, Panzem), carboxyamidotriazole (CAI), combretastatin A4 prodrug (CA4P), SU6668, SU11248, BMS-275291, COL-3, EMD 121974, IMC-IC11, IM862, TNP-470, celecoxib (Celebrex), rofecoxib (Vioxx), interferon alpha, interleukin-12 (IL-12) or any of the compounds identified in Science Vol. 289, Pages 1197-1201 (Aug. 17, 2000) which is expressly incorporated herein by reference, biological response modifiers (e.g., interferon, bacillus calmette-guerin (BCG), monoclonal antibodies, interluken-2, granulocyte colony stimulating factor (GCSF), etc.), PGDF receptor antagonists, herceptin, asparaginase, busulphan, carboplatin, cisplatin, carmustine, chlorambucil, cytarabine, dacarbazine, etoposide, flucarbazine, fluorouracil, gemcitabine, hydroxyurea, ifosphamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, thiotepa, tomudex, topotecan, treosulfan, vinblastine, vincristine, mitoazitrone, oxaliplatin, procarbazine, streptocin, taxol, taxotere, analogs/congeners and derivatives of such compounds, as well as other antitumor agents not listed here.
Additionally or alternatively, in some applications such as those where it is desired to grow new cells or to modify existing cells, the substances delivered in this invention may include cells (mucosal cells, fibroblasts, stem cells or genetically engineered cells), as well as genes and gene delivery vehicles like plasmids, adenoviral vectors or naked DNA, mRNA, etc., injected with genes that code for anti-inflammatory substances, etc., and, as mentioned above, osteoclasts that modify or soften bone when so desired.
Additionally or alternatively to being combined with a device and/or a substance releasing modality, it may be ideal to position the device in a specific location upstream in the mucous flow path (i.e., frontal sinus or ethmoid cells). This could allow the deposition of fewer drug releasing devices, and permit the “bathing” of all the downstream tissues with the desired drug. This utilization of mucous as a carrier for the drug may be ideal, especially since the concentrations for the drug may be highest in regions where the mucous is retained; whereas non-diseased regions with good mucous flow will be less affected by the drug. This could be particularly useful in chronic sinusitis, or tumors where bringing the concentration of drug higher at those specific sites may have greater therapeutic benefit. In all such cases, local delivery will permit these drugs to have much less systemic impact. Further, it may be ideal to configure the composition of the drug or delivery system such that it maintains a loose affinity to the mucous permitting it to distribute evenly in the flow. Also, in some applications, rather than a drug, a solute such as a salt or other mucous soluble material may be positioned at a location whereby mucous will contact the substance and a quantity of the substance will become dissolved in the mucous thereby changing some property (e.g., pH, osmolarity, etc.) of the mucous. In some cases, this technique may be used to render the mucous hyperosmolar so that the flowing mucous will draw water from polyps, edematous mucosal tissue, etc., thereby providing a desiccating therapeutic effect.
Additionally or alternatively to substances directed towards local delivery to affect changes within the sinus cavity, the nasal cavities provide unique access to the olfactory system and thus the brain. Any of the devices and methods described herein may also be used to deliver substances to the brain or alter the functioning of the olfactory system. Such examples include, the delivery of energy or the deposition of devices and/or substances and/or substance delivering implant(s) to occlude or alter olfactory perception, to suppress appetite or otherwise treat obesity, epilepsy (e.g., barbiturates such as phenobarbital or mephoobarbital; iminostilbenes such as carbamazepine and oxcarbazepine; succinimides such as ethylsuximide; valproic acid; benzodiazepines such as clonazepam, clorazepate, diazepam and lorazepam, gabapentin, lamotrigine, acetazolamide, felbamate, levetiraceam, tiagabine, topiramate, zonisamide, etc.), personality or mental disorders (e.g., antidepressants, anti-anxiety agents, antipsychotics, etc.), chronic pain, Parkinson's disease (e.g., dopamine receptor agonists such as bromocriptine, pergolide, ropinitrol and pramipexole; dopamine precursors such as levodopa; COMT inhibitors such as tolcapone and entacapone; selegiline; muscarinic receptor antagonists such as trihexyphenidyl, benztropine and diphenhydramine) and Alzheimer's, Huntington's Disease or other dementias, disorders of cognition or chronic degenerative diseases (e.g., tacrine, donepezil, rivastigmine, galantamine, fluoxetine, carbamazepine, clozapine, clonazepam and proteins or genetic therapies that inhibit the formation of beta-amyloid plaques), etc.
1-5G111 show a device 160 and method for delivery of a pressure expandable stent 166. This device 160 comprises a flexible catheter 162 having a balloon 164 thereon. Initially, as shown in
1 and 5L show a forward rotary cutting catheter device 700 that comprises a flexible outer tube 702 and a flexible inner tube 704 disposed coaxially and rotatably mounted within the outer tube 702. One or more bearings 708 (e.g., a helical bearing or a series of individual cylindrical bearings) may be disposed between the outer tube 702 and inner tube 704, as shown. Alternatively, one or both apposing tube surfaces may be made of, lined with, or be coated by etc., a lubricious material such as silicone or PTFE to facilitate movement. A rotating cutter 706 is positioned on the distal end of the inner tube 704. In operation, as shown in
It is to be understood that any of the devices described within this document may be further modified to include any one of the following devices within its structure: electromagnetic positioning sensor/detector (Biosense/JNJ, Surgical Navigation Technologies/Medtronic, Calypso Medical), RF sensor/transmitter, magnetic direction localizer (Stereotaxis, Inc.), thermal sensor, radiopaque composition, radioactive detection emitter/sensor, ultrasonic scanner/transmitter/receiver, Doppler scanner, electrical stimulator, fiber optic, digital optic, local diagnostic chip containing elements responsive to the presence or absence of certain substances and therefore having the ability to diagnose the presence of fungus, microbes, viruses, blood, abnormal mucous content, cancer cells, drugs of abuse, genetic abnormalities, metabolic bi-products, etc.
It is to be further understood that any and all of the devices described in this patent application may incorporate, or may be used in conjunction with, endoscopes. Such endoscopes will typically include light transmitting optical fibers for casting light in the area to be viewed by the scope and image transmitting optical fibers for carrying an image received by the scope to an eyepiece or monitor device located outside the patient's body. In some embodiments a scope, such as a disposable and/or flexible scope, may be affixed to the working device. Examples of such endoscopes that are suitable for incorporation into the working devices of this invention include that described in U.S. Pat. Nos. 4,708,434; 4,919,112; 5,127,393; 5,519,532; 5,171,233, 5,549,542, 6,551,239 and 6,572,538; as well as published United States Patent Application No. 2001/0029317A1, issued as U.S. Pat. No. 6,616,601 on Sep. 9, 2003, the entireties of which are expressly incorporated herein by reference.
It is to be further understood that any catheters or elongate flexible devices of this invention may include design elements that impact performance features, which include but are not limited to, durability, flexibility, stiffness, length, profile, lubricity, trackability, steerability, torqueability, deflectability, guidance, and radiopacity. Design elements can include, but are not limited to, use of various polymers and metals, use of varying durometer materials to establish a desired flexibility gradient along the device, blending/mixing/layering/co-extruding etc., various materials, using bearings or lubricious coatings or lubricious materials (e.g., silicone, PTFE, parylene, polyethene, etc.) where two or more surfaces will move relative to each other (e.g., guidewire or instrument lumen, deflecting tendon in lumen, etc.), use of braiding or springs to increase torque control over the device, using materials (e.g., barium, tantalum, etc.) to increase polymer radiopacity, and use of elements to predictably deflect various sections of the catheter (e.g., tension straps or wires, shape memory alloys such as nitinol, etc.).
It is to be further understood that any of the catheters, scopes, elongate working devices or other devices disclosed in this patent application may be rendered steerable or volitionally bendable, unless to do so would make such device inoperative for its intended purpose. Steerable catheters and scopes are well known in the art and may utilize mechanical steering assemblies (e.g., pull wires, hinges, etc.) or shape memory materials (e.g., nickel titanium alloys, shape memory polymers, etc.) to induce the device to undergo the desired bending or curvature after it has been inserted into the body. Examples of apparatus and construction that may be used to render these devices steerable or volitionally bendable include but are not limited to those described in U.S. Pat. No. 5,507,725 (Savage et al.); U.S. Pat. No. 5,656,030 (Hunjan et al.); U.S. Pat. No. 6,183,464 (Webster); U.S. Pat. No. 5,251,092 (Qin et al.); U.S. Pat. No. 6,500,130 (Kinsella et al.); U.S. Pat. No. 6,571,131 (Nguyen); U.S. Pat. No. 5,415,633 (Lazarus et al.); U.S. Pat. No. 4,998,916 (Hammerslag et al.); U.S. Pat. No. 4,898,577 (Badger et al.); U.S. Pat. No. 4,815,478 (Buchbinder et al.); and published United States Patent Application Nos. 2003/0181827A1 (Hojeibane et al.), issued as U.S. Pat. No. 7,128,718 on Oct. 31, 2006 and 2003/0130598A1 (Manning et al.) issued as U.S. Pat. No. 7,493,156 on Feb. 17, 2009, the entireties of which are expressly incorporated herein by reference.
As described above in connection with other embodiments such as those shown in
1 show a self-expanding stent and delivery system 760 comprising a flexible outer sheath 762, a flexible inner tube 764 and a stent 768. This stent differs from the stent 748 of
1 show a telescoping system 800 comprising a flexible catheter 802, a flexible scope 804 and a guidewire 806. The flexible scope 804 comprises a plurality of light transmitting pathways 808 (e.g., optical fibers) that transmit light in the distal direction from a light source (not shown) and out of the distal end of the scope 804 such that the light is cast onto the object or anatomical structure to be viewed. Also, the scope comprises an image transmitting pathway 810 (e.g., optical fiber and lens) that carries reflected light from distal end of the scope to an eyepiece or monitor on which the image may be viewed. The scope also has a guidewire lumen 805 extending therethrough and opening through its distal end. The scope 804 is advanceable through the flexible catheter 802 and a guidewire 806 that is advanceable through a guidewire lumen 805 of the scope, as shown. In routine operation, the telescoping system 800 may be inserted into the nose and the scope 804 may be utilized to view an anatomical structure, such as the ostium of a paranasal sinus, and facilitate advancement of the guidewire into that anatomical structure. Thereafter, the scope may be advanced over the guidewire and into the anatomical structure (e.g., though the ostium and into the interior of the paranasal sinus). The scope may then be used to examine the anatomical structure (e.g., to view the condition of the mucosa lining the paranasal sinus and to look for signs of infection, tumors, etc.). The catheter 802 may then be advanced over the scope 804 and into the anatomical structure (e.g., the catheter tip may be advanced through the ostium and into the paranasal sinus). Thereafter, the scope 804 may be removed and a diagnostic or therapeutic substance as defined hereabove may be infused through the catheter 802 and/or another working device, including but not limited to the working devices shown in
In some applications of the invention, it may be desirable to break bone, such as the thin bone that forms the periphery of a sinus ostium.
1-5Y11111 show various substance delivery implants that may be implanted into the nasal cavities, paranasal sinuses, middle or inner ear, nasopharynx, etc., to deliver a diagnostic or therapeutic substance as defined herein. These devices may be formed of permanent or bio-absorbable material. In many instances, these devices will be formed of a polymer (e.g., Hydron, hydrogel, collagen, etc.) within which the diagnostic or therapeutic substance is contained or a polymer or metal that is coated with or otherwise contains the substance.
D. Pre-Shaped Guide Catheters
In some of the methods of the invention, it will be desirable to plug the ostium of a sinus or another opening such as the nasolacrimal duct or the nasopharyngeal opening into the Eustachian tube. Thus, any of the above described guide catheters 120, 128, 136, 144 may be equipped with a plug on its distal tip such that when its distal end enters the sinus ostium it will plug the sinus thereby preventing fluid from exiting the sinus through the ostium. An example of one such procedure is shown in
E. Devices and Methods for Treatment within Paranasal Sinuses:
F. General Examples of Interventions Using the Occluder & Access Devices and/or Working Devices
In general, diagnostic interventions in accordance with this invention may include:
a) anatomic studies where obstructions, sizes, parameters or abnormalities in anatomy are visualized and/or identified, b) dynamic studies where gas, mucous or fluid is introduced into the nose, sinus, nasal cavity, nasopharynx, Eustachian tube, inner or middle ear, etc. and the movement of such materials is monitored to assess drainage or gas flow issues, and
c) perturbation studies where an agent (e.g., an allergen, irritant, agent that induces mucous production, etc.) is introduced into the nose, sinus, nasal cavity, nasopharynx, Eustachian tube, inner or middle ear, etc., and the patient's response and/or flow of the endogenously produced mucous or other secretions is assessed. Examples of procedures that may be used to perform these types of diagnostic interventions include, but are not limited to, the following:
1. Gaining Access To Sinus:
Access to one of more of the paranasal sinuses is gained by advancement of catheter(s) into the sinus or sinuses of interest. A guidewire may be inserted into the sinus first and the catheter may then be advanced over the guidewire and into the sinus. In some cases, a sinus ostium guide catheter of the type shown in
2. Mucous Flow Study:
Optionally, after catheter access to the sinus has been gained, an imageable contrast substance or radioactive material such as microbeads or a flowable contrast medium (e.g., an iodinated contrast solution with or without a thickening agent to adjust its viscosity to that of mucous) that may have a consistency similar to that of mucous may be injected into the sinus. An imaging or scanning technique (e.g., X-ray, fluoroscopy, CT scan, ultrasound, MRI, radiation detector, gamma camera, etc.) may then be used to observe the flow of the contrast medium through and out of the sinus. In some cases a fluoroscope with a C-arm may be used in a fashion similar to that used in coronary artery catheterization and angiography procedures to allow the clinician to view the movement of the contrast medium from different vantage points or angles. To facilitate flow of the contrast medium from the sinus, the previously inserted catheter(s) and/or guidewires and/or scope(s) may be backed out of the sinus and ostium or removed completely, to allow normal flow to occur. The patient's head and/or other body parts may be repositioned to observe different postural drainage effects. In this manner, the clinician may specifically locate and identify which anatomical structures are obstructing or interfering with normal mucous flow from the sinus.
3. Air Flow Study:
Optionally, after access to the sinus has been gained as described in No. 1, above, an imageable or traceable gas, such as a radiolabeled gas, radiopaque gas or a gas with imageable or radioactive microbeads therein, may be injected through a catheter and into the sinus. An imaging device or tracing device (e.g., radiation detector, gamma camera, X-ray, fluoroscopy, CT scan, ultrasound, MRI) may then be used to observe subsequent movement or dissipation of the gas as it passes out of the sinus and/or equilibrates with other sinus cavities. In this manner, the clinician may determine whether normal gas exchange in the sinus is occurring and may locate and identify any anatomical structures or irregularities that are obstructing or interfering with normal gas flow and/or gas exchange.
4. Anatomic Dimension Study:
An entire paranasal sinus or other anatomical passageway or structure may be filled with an imageable substance or otherwise measured to determine its actual dimensions and/or configuration. In some such studies, access to a paranasal sinus will be gained as described in No. 1, above, and the sinus may be filled with an imageable substance (e.g., contrast medium). A suitable imaging technique (e.g., X-ray, fluoroscopy, CT scan, ultrasound, MRI, radiation detector, gamma camera, etc.) may then be used to determine the size and shape of the sinus. Again, in such procedure, a moveable imaging apparatus such as a fluoroscope with a C-arm may be used to view and measure the contrast filled sinus from different vantage points or angles. One example of such a procedure is shown in
5. Endoscopic Study:
A flexible and/or steerable endoscope, as described above, may be inserted into the nose, sinus, nasal cavity, nasopharynx, Eustachian tube, inner or middle ear, etc., and used to visually examine the anatomy and/or to observe a treatment and/or to assess the efficacy or completeness of a previously rendered treatment. In cases where it is desired to view the interior of a paranasal sinus, access to the sinus may be gained as described in No. 1, above, and the endoscope may be advanced into the interior of the sinus either directly or over a guidewire.
6. Transillumination Study:
A flexible light emitting instrument (e.g., a catheter having a powerful light emitting apparatus at its distal end) may be advanced into the nose, paranasal sinus, nasal cavity, nasopharynx, Eustachian tube, inner or middle ear, etc., and used to illuminate anatomical structures. Direct or endoscopic observation may then be made from outside the body and/or from other locations within the nose, sinus, nasal cavity, nasopharynx, Eustachian tube, inner or middle ear, orbit, cranial vault, etc., to observe anatomical structures and/or to detect aberrant openings or leaks through which the light passes. In cases where the light emitter and/or the viewing instrument (e.g., endoscope) is/are positioned within paranasal sinus(es) access to the sinus(es) may be gained as described in No. 1, above, and the light emitter and/or viewing instrument may then be advanced into the sinus(es) either directly or over guidewire(s).
7. Other Imaging Studies:
Other imaging techniques such as MRI, CT, etc., in combination with any of the modalities set forth in Nos. 1-6, above, and modifications may be made to any of those techniques to adjust for sinus anatomy or other pathology.
After any or all of the elected diagnostic studies have been completed, one or more working devices, such as the flexible devices described herein and shown in
As shown in the example of
In
Thereafter, as shown in
After all of the desired procedures have been completed, the anterior occluders 14, 40 and posterior occluder (not shown on
G. Cochlear Implant Procedure
Thereafter, a sound receiving device or transducer 908 is advanced through the catheter 900 and positioned in the tympanic cavity TC. The sound receiving device or transducer 908 may be of any type that is a) sufficiently small to pass through the Eustachian tube ET and into the tympanic cavity TC, and b) useable to perform the desired function of converting sound waves to electrical impulses and delivering such electrical impulses to the cochlear electrode array 906. A microphone/power/electronics device 910 may be positioned in the outer ear canal, as shown in
Turning now to
Once guidewire or elongated probe 1.004 has been properly placed, working device 1.006 is next passed over the guidewire or elongated probe 1.006, under visualization via fluoroscope 1.0001 and/or an endoscope (not shown) that has been inserted adjacent catheter or tube 1.002, to place the working end of working device 1.006 in the target location where a surgical procedure is to be performed. Typically, the guidewire or elongated probe remains in place during the procedure. Under the same type(s) of visualization, the working (distal) end of working device is then actuated to perform the desired surgical procedure. In the case of a dilatation catheter, the balloon at the distal end portion of catheter 1.006 is expanded once it has been located across the ostium. This expansion acts to open the ostium to allow proper mucus flow, as was described in more detail above.
After performance of the desired surgical procedure, the working device 1.006 is deactivated and withdrawn from the patient, after which the remaining devices are withdrawn to complete the procedure.
By using the devices and methods described herein, at least the need for fluoroscopic visualization of the placement of the guidewire/elongated probe can be reduced or eliminated. Further optionally, all fluoroscopic visualization needs may be eliminated in some surgical circumstances.
It is to be appreciated that the devices and methods of the present invention relate to the accessing and dilatation or modification of sinus ostia or other passageways within the ear, nose and throat. These devices and methods may be used alone or may be used in conjunction with other surgical or non-surgical treatments, including but not limited to the delivery or implantation of devices and drugs or other substances as described in co-pending U.S. patent application Ser. No. 10/912,578, issued as U.S. Pat. No. 7,361,186 on Apr. 22, 2008.
In
In
Although scope 1.008 may be useful to reduce or eliminate the need for fluoroscopic visualization during placement of sinus guide 1.002 and/or for visualization of the procedure performed by working device 1.006, it does not provide stand-alone capability to see inside the sinus (e.g., sphenoid sinus 1.016 or other sinus of interest), and therefore cannot provide sufficient visual feedback for use in guiding guidewire 1.01 into the desired sinus (e.g., frontal sinus, or some other sinus of interest) or sufficient visual image confirmation of correct placement of guidewire 1.01 into the desired sinus.
Further, depending upon the particular configuration of the sinus passageways to be traversed to gain access to a target ostium, the scope 1.008, due to physical limitations (e.g., outside diameter, degree of rigidity, etc.) may be unable to visualize as deep as the location of the ostium of interest. For example,
In order to overcome these and other problems, the guidewire devices 1.01 of the present invention include their own light emitting capability. By illuminating a distal end portion of guidewire 1.01, a process known as transillumination occurs as guidewire 1.01 traverses through the sinus passageways, passes through an ostium and enters a sinus cavity. Transillumination refers to the passing of light through the walls of a body part or organ. Thus, when guidewire 1.01 is located in a sinus, the light emitted from guidewire 1.01 passes through the facial structures and appears as a glowing region on the skin (e.g., face) of the patient. It is noted that the light emitted from scope 1.008, such as positioned in
Coil 1.0c may be formed from a stainless steel wire, for example. The diameter of the coil wire can be between about 0.004 and about 0.008 inches, typically about 0.006 inches. Alternative materials from which coil 1.0c may be formed include, but are not limited to: ELGILOY®, CONICHROME® or other biocompatible cobalt-chromium-nickel alloy; nickel-titanium alloys, or other known biocompatible metal alloys having similar characteristics. Further alternatively, distal end portion may comprise a braided metallic construction of any of the aforementioned materials in lieu of a coil.
The external casing of the proximal portion 1.0p can be made from a polyimide sheath, a continuous coil (optionally embedded in polymer or having polymer laminated thereon), a hypotube (e.g., stainless steel hypotube), a laser-cut hypotube, a cable tube, or a tube made from PEBAX® (nylon resin) or other medical grade resin. In any of these cases the construction needs to meet the required torquability, pushability and tensile requirements of the device.
In the example shown, coil 1.0c is joined to proximal portion 1.0p by solder, epoxy or other adhesive or mechanical joint. One or more illumination channels 1.0i are provided in device 1.01 and extend the length thereof. Illumination channels 1.0i are configured to transport light from the proximal end of device 1.01 to and out of the distal end of device 1.01. In the example shown, two illumination channels are provided, each comprising a plastic illumination fiber. The plastic used to make the illumination fibers is compounded for light transmission properties according to techniques known and available in the art. As one example, ESKATM (Mitsubishi Rayon), a high performance plastic optical fiber may be used, which has a concentric double-layer structure with high-purity polymethyl methacrylate (PMMA) core and a thin layer of specially selected transparent fluorine polymer cladding. In one example, illumination fibers each have an outside diameter of about 0.010″. The illumination fibers can have an outside diameter in the range of about 0.005 inches to about 0.010 inches. Alternatively, a single plastic illumination fiber 1.0i may be used that has an outside diameter of about 0.020″. Further alternatively, glass illumination fibers may be substituted which are much smaller in outside diameter, e.g., about 0.002″. In this case, more illumination fibers may be provided in a bundle, e.g., about six to fifty glass fibers 1.0i may be provided.
The distal end of device 1.01 is sealed by a transparent (or translucent) seal 1.0s which may be in the form of epoxy or other transparent or translucent adhesive or sealing material. Seal 1.0s maintains the distal ends of illumination fibers 1.0i coincident with the distal end of device 1.01 and also provides an atraumatic tip of the device 1.01. Further, seal 1.0s prevents entrance of foreign materials into the device. The distal end can be designed to either focus or distribute the light as it emanates therefrom, to achieve maximum transillumination effects. In this regard, the distal end can include a lens, prism or diffracting element.
The proximal end of device 1.01 is also sealed by a transparent (or translucent) seal 1.0ps which may be in the form of epoxy or other transparent or translucent adhesive or sealing material. Seal 1.0ps maintains the proximal ends of illumination fibers 1.0i coincident with the proximal end of device 1.01. The proximal end of device 1.01 may be further prepared by grinding and polishing to improve the optical properties at the interface of the proximal end of device 1.01 with a light source. The illumination fibers 1.0i at locations intermediate of the proximal and distal ends need not be, and typically are not fixed, since no mapping of these fibers is required, as device 1.01 provides only illumination, not a visualization function like that provided by an endoscope. Further, by leaving illumination fibers free to move at locations between the proximal and distal ends, this increases the overall flexibility and bendability of device 1.01 relative to a similar arrangement, but where the illumination fibers 10i are internally fixed.
The outside diameter of device 1.01 may be in the range of about 0.025 inches to about 0.040 inches, typically about 0.030 to 0.038 inches, and in at least one embodiment, is about 0.035″:1:0.005″. At least the distal portion 1.0d of device 1.01 is provided with a core support 1.0cw that is contained therein. In the example shown in
Core support 10cw particularly increases the pushability and the torquability of coil 1.0c which, by itself, is quite flexible and twistable. Combined with the core support 1.0cw, the distal portion is much more effective at transferring pushing and torquing forces without buckling or twisting. Additionally, core support 1.0cw may be plastically deformed or memory set into a bent shape, an example of which is shown in
The illumination fibers, as noted above, can be free to move about radially within the device. Further, there is no need to center the illumination fibers 1.0i with respect to device 1.01 even at the distal and proximal ends of the device.
The plastic or glass illumination fibers 1.0i of the device shown in
Device 1.01 in
Any of the devices 1.01 described herein may optionally include one or more radiopaque markers and/or electromagnetic coils on the tip of the device 1.01 and/or elsewhere along the device for enhancing visibility by fluoroscopy systems, image guided surgery (IGS) systems, or other visualization systems.
The distal portion 1.0d includes a transparent proximal end portion 1.0dp that mounts over the distal end of proximal end portion 1.0p of the device 1.01. The transparent portion 1.0dp permits the illumination emitted from illumination member 1.0i or 1.0id to pass out of the device 1.01 at the location of transparent portion 1.0dp. The illumination member(s) 1.0i or 1.0id thus terminate at the proximal end portion 1.0dp of the distal end portion of device 1.01. Distally of this transparent portion 1.0dp, the distal portion 1.0dd of distal end portion 1.0d of device 1.01 extends as a floppy guidewire leader or tip. This floppy guidewire leader or tip 1.0dd may include a coiled section 1.0c and may optionally include a core support 1.0cw in the manner described above with regard to
Transparent portion 1.0dp may be provided as a clear plastic or glass integral tube, or may have openings or windows 1.0t provided therein (see the partial view of
Device 1.01 should be readily connectable to and disconnectable from a power source to enable attachment for providing illumination for positioning the guidewire 1.01 and/or other devices during a procedure, detachment to allow another device to be slid onto the guidewire 1.01 from a free proximal end thereof, and reattachment to again provide illumination, to assist in guidance/visualization of the device being passed over the guidewire 1.01, for example.
Connector 2.01 includes a proximal channel, slot or bore 2.2 that has an inside dimension or circumference that is slightly greater than the outside diameter or circumference of device 1.01 at the proximal end portion 1.0p. A quick release locking mechanism 2.4 is provided for locking and unlocking device 1.01 within connector 2.01. Quick release locking mechanism is biased toward the locking position shown in
Light cable 1.032 generally has a much larger inside diameter than the inside diameter or combined inside diameters of the illumination fibers 1.0i. Accordingly, the proximal end portion of connector 2.01 provides a tapering or funnel shaped pathway 2.6 having a proximal inside diameter that is substantially equivalent to the inside diameter of cable 1.032 or greater, and which tapers to a distal inside diameter that is about the same or only slightly greater than the inside diameter or combined inside diameters of the illumination fiber(s), or alternatively, that is about the same or only slightly greater than the outside diameter of the proximal end of device 1.01. The light cable 1.032 generally has a larger diameter bundle of illumination fibers than that contained within the illuminating guidewire 1.01. Accordingly, the tape 2.6 is used to transition between the larger bundle in the light cable 1.032 and the smaller bundle in the guidewire 1.01. With this arrangement, light delivered through light cable 1.032 is concentrated or focused down to a pathway where most of the light can be transmitted through the illumination fibers.
To insert device 1.01 into connector 2.01, an operator retracts quick connect locking mechanism 2.4 to the open position shown in
In the example shown in
The proximal end of connector 2.01 is provided with a light post 2.8 that is configured to mate with a connector on the distal end of a light cable extending from a conventional endoscope light source. For example, light post 2.8 may be an ACMI light post (ACMI Corporation) or other standard connector typically used to connect endoscopes to operating room light sources. Because the cable extending from an operating room light source generally has a much larger inside diameter than the inside diameter or combined inside diameters of the illumination fibers of device 1.01, and larger than the diameter of the proximal end of guidewire 1.01, the proximal end portion of connector 2.01 includes a light tapering or funnel-shaped pathway 2.6 like that described above with regard to
The quick release locking mechanism 2.4 in this example includes a collet 2.4c that is configured to center the proximal end of device 1.01 with the distal end of tapering pathway 2.6. A threaded cap 2.4d is threaded over mating threads 2.4t on the body of connector 2.01, so that when cap 2.4d is torqued in a direction to advance cap 2.4d proximally with respect to the body of connector 2.01, inner ramped or cammed surfaces 2.4e of cap 2.4d ride over outer ramped or cammed surfaces 2.4f of collet 2.4c, thereby functioning as a pin vise and clamping collet 2.4c against the proximal end portion of device 1.01 to clamp and maintain device 1.01 in its current position relative to connector 2.01. To insert device 1.01, cap 2.4d is rotated in a reverse direction from that described above to open the distal opening of the inner channel 2.4g of collet 2.4c to a dimension larger than the outside diameter of the proximal end of device 1.01, so that device 1.01 can be easily slid through the channel 2.4g until the proximal end of device 1.01 abuts the proximal end portion of collet 2.4c, or approximates the same. The cap 2.4d is then turned with respect to the body of connector 2.01 to clamp device 1.01 into position, as described above. Removal of device 1.01 can be performed by turning cap 2.4d in a reverse direction relative to connector body 2.01, thereby loosening the grip of collet 2.4c on device 1.01, after which device 1.01 can be easily slid out from connection with connector 2.01. Components of connector 2.01 may be made from metal, such as stainless steel or other biocompatible metals, or temperature-resistant thermosetting polymer, for example.
Light post 2.8 is rotatable with respect to the light cable 1.032 of the light source 1.30 when connector 2.01 is connected to the distal end connector of the light cable 1.032. This allows device 1.01, when connected to connector 2.01 in this arrangement, to be rotated during use without building up significant twisting or rotational counter forces within the light cable 1.032. For example, in the light post 2.8 shown, the female receptacle (not shown) of the light cable 1.032 couples over light post 2.8 and engages in groove 2.8g, about which the female receptacle is then rotatable relative to light post 2.8.
Turning now to
In
Once the surgeon is satisfied that the distal end of the sinus guide 1.002 is positioned close enough to the appropriate ostium 1.034, illuminating guidewire 1.01, connected to a light source as described by any of the techniques mentioned above, is inserted through sinus guide 1.002 and advanced therethrough, see
While there may be some diffuse transillumination on the forehead of the patient overlying the frontal sinus 1.036 as the light emitting portion of device 1.01 approaches the ostium 1.034, the glow on the forehead becomes brighter and smaller in dimension (more focused) as the light emitting portion passes through the ostium 1.034 and enters the frontal sinus 1.036,
Once properly positioned, the proximal end of device 1.01 is disconnected from connector 2.01, while leaving guidewire 1.01 in its current position. A working device 1.006, for example a balloon catheter, is the introduced over guidewire 1.01 and advanced thereover so that the proximal end of device 1.01 extends proximally beyond a proximal end of device 1.006. Device 1.01 is then reconnected to connector 20 so that light is again emitted from the light emission portion of the distal end portion of device 1.01. Thus it can be visually confirmed, without radiography, that the distal end portion of the guidewire 1.01 remains properly in the frontal sinus 1.036 as the working device 1.006 is advanced toward ostium 1.034 and the balloon of working device 1.006 is extended across the ostium 1.034. The proper positioning of the working end (distal end portion) of working device 1.006 can be visualized with the scope and/or fluoroscopy.
Once proper placement of the working device 1.006 has been confirmed, working device 1.006 is used to perform a diagnostic or therapeutic procedure. In this particular example, the procedure is dilatation of the frontal sinus ostium 1.034 by expansion of the balloon thereagainst, to enlarge the opening of the ostium 1.034. However, it will be appreciated that the present invention may also be used to dilate or modify any sinus ostium or other man-made or naturally occurring anatomical opening or passageway within the nose, paranasal sinuses, nasopharynx or adjacent areas. Further, other working tools may be inserted and used according to these same techniques. After the completion of the procedure, sinus guide 1.002, guidewire 1.01 and working device 1.006 are withdrawn and removed, completing the procedure, see
Illuminating guidewire device 1.01 can also be used to facilitate visualization and placement of the sinus guide 1.002 in the procedure described above with regard to
Additionally, this technique can be used to visualize placement of the guidewire 1.01 up to and into the desired ostium 1.034. Alternatively, this can be carried out without the sinus guide 1.002, wherein the guidewire 1.01 is inserted and the scope 1.008 can be used to visualize placement of guidewire 1.01 into the target ostium with the assistance of the light emitted by the scope 1.008 in addition to the light emitted by guidewire 1.0.
In any of these procedures where a scope 1.008 is used for visualization and an illuminating guide wire is inserted, some transillumination of the target sinus may occur from the light emitted by the scope 1.008 alone. However, this transillumination will be diffuse and show a rather dim, large area of transillumination on the patient's skin. When the illumination guidewire is inserted and advanced, as noted earlier, a smaller, brighter transillumination spot will be visible when the illuminating portion of the guidewire has entered the sinus. Additionally, even before entering the sinus, the light emitted from the guidewire will produce a moving transillumination spot at guidewire 1.01 is advance, which also helps distinguish the location of the distal portion of the guidewire, relative to any diffuse transillumination produced by the scope light.
If the guidewire 1.01 is advanced into an ostium other than the target ostium (e.g., ostium 1.035 shown in
Thus, by using an illuminating guidewire device 10in the methods as described above, the use of fluoroscopy or other X-ray visualization can be reduced is not required to confirm proper placement of the guidewire in some cases.
Similar procedures may be carried out in other sinuses. For example, a similar procedure to that described above with regard to
It is further noted that some wavelengths of light may be more effective in producing the transillumination effects described herein, for the purpose of locating the position of the guidewire. In this regard, particular wavelengths of visible light can be selected for this purpose. Alternatively, or in addition, infrared wavelengths may be particularly effective. In this regard, guidewires that employ illuminating fibers may be provided with a filter 1.2 to define the color/wavelength of the light emitted by device 1.01. As schematically shown in
Another optional feature that guidewire 1.01 may be provided with is the ability to emit strobed, flashing or flickering light. The transillumination produced by a flashing light can be further distinguished from diffuse transillumination produced by other light sources, such as endoscopes, for example, since the transillumination produced by the guidewire 1.01 in this case will flicker or vary in intensity between bright and dim. To produce this type of light, either a light source having strobing capability could be connected to the device 1.01, or connector 2.01 may be provided with this capability. When using a laser light source or an LED as the light emitter, as described in embodiments above, a blinking or strobing effect can be electronically generated according to techniques known in the electronics and lighting arts.
Other instruments that are designed to be inserted into a sinus, or at least to be positioned at the ostium of a sinus can also be provided with illumination capability according to any or all of the features described above with regard to illumination guidewires.
In one preferred embodiment for adult applications, balloon catheter 1.201 has an overall length of approximately 43.5 cm and its shaft 1.26 has an outer diameter of about 0.058 inches. Further details about integrated wire dilatation catheters that may be configured with a light emitter in a manner as described herein can be found in co-pending application Ser. No. 11/438,090 filed May 18, 2006 and titled “Catheters with Non-Removable Guide Members Useable for Treatment of Sinusitis, issued as U.S. Pat. No. 8,951,225 on Feb. 10, 2015. Application Ser. No. 11/438,090, issued as U.S. Pat. No. 8,951,225 on Feb. 10, 2015 is hereby incorporated herein, in its entirety, by reference thereto.
While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. It is to be appreciated that the invention has been described hereabove with reference to certain examples or embodiments of the invention but that various additions, deletions, alterations and modifications may be made to those examples and embodiments without departing from the Intended spirit and scope of the invention. For example, any element or attribute of one embodiment or example may be incorporated into or used with another embodiment or example, unless to do so would render the embodiment or example unsuitable for its intended use. All reasonable additions, deletions, modifications and alterations are to be considered equivalents of the described examples and embodiments and are to be included within the scope of the following claims.
This application is a continuation-in-part of U.S. patent application Ser. No. 10/829,917 filed on Apr. 21, 2004, issued as U.S. Pat. No. 7,654,997 on Feb. 2, 2010, and is also a continuation-in-part of U.S. patent application Ser. No. 11/522,497 filed on Sep. 15, 2006, issued as U.S. Pat. No. 7,559,925 on Jul. 14, 2009; the entireties of which are herein incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 446173 | Hancock | Feb 1891 | A |
| 504424 | De Pezzer | Sep 1893 | A |
| 513667 | Buckingham | Jan 1894 | A |
| 705346 | Hamilton | Jul 1902 | A |
| 798775 | Forsyte | Sep 1905 | A |
| 816792 | Green | Apr 1906 | A |
| 1080934 | Shackleford | Dec 1913 | A |
| 1200267 | Sunnergren | Oct 1916 | A |
| 1650959 | Pitman | Nov 1927 | A |
| 1735519 | Vance | Nov 1929 | A |
| 1828986 | Stevens | Oct 1931 | A |
| 1878671 | Cantor | Sep 1932 | A |
| 2201749 | Vandergrift | May 1940 | A |
| 2525183 | Robison | Mar 1947 | A |
| 2493326 | Trinder | Jan 1950 | A |
| 2847997 | Tibone | Aug 1958 | A |
| 2899227 | Jeanrenaud | Aug 1959 | A |
| 2906179 | Bower | Sep 1959 | A |
| 2995832 | Alderson | Aug 1961 | A |
| 3009265 | Bexark | Nov 1961 | A |
| 3037286 | Bower | Jun 1962 | A |
| 3173418 | baran | Mar 1965 | A |
| 3347061 | Stuemky | Oct 1967 | A |
| 3376659 | Asin et al. | Apr 1968 | A |
| 3384970 | Avalear | May 1968 | A |
| 3393073 | Reutenauer et al. | Jul 1968 | A |
| 3435826 | Fogarty | Apr 1969 | A |
| 3447061 | Russell et al. | May 1969 | A |
| 3469578 | Bierman | Sep 1969 | A |
| 3481043 | Esch | Dec 1969 | A |
| 3486539 | Jacuzzi | Dec 1969 | A |
| 3506005 | Gilio et al. | Apr 1970 | A |
| 3509638 | Macleod | May 1970 | A |
| 3515888 | Lewis | Jun 1970 | A |
| 3527220 | Summers | Sep 1970 | A |
| 3531868 | Stevenson | Oct 1970 | A |
| 3552384 | Pierie et al. | Jan 1971 | A |
| 3624661 | Shebanow | Nov 1971 | A |
| 3731963 | Pond | May 1973 | A |
| 3766924 | Pidgeon | Oct 1973 | A |
| 3792391 | Ewing | Feb 1974 | A |
| 3800788 | White | Apr 1974 | A |
| 3802096 | Matern | Apr 1974 | A |
| 3804081 | Kinoshita | Apr 1974 | A |
| 3834394 | Hunter et al. | Sep 1974 | A |
| 3847145 | Grossan | Nov 1974 | A |
| 3850176 | Gottschalk | Nov 1974 | A |
| 3856000 | Chikama | Dec 1974 | A |
| 3859993 | Bitner | Jan 1975 | A |
| 3871365 | Chikama | Mar 1975 | A |
| 3889776 | Postma | Jun 1975 | A |
| 3894538 | Richter | Jul 1975 | A |
| 3903893 | Scheer | Sep 1975 | A |
| 3910617 | Scalza et al. | Oct 1975 | A |
| 3921636 | Zaffaroni | Nov 1975 | A |
| 3948254 | Zaffaroni | Apr 1976 | A |
| 3948262 | Zaffaroni | Apr 1976 | A |
| 3967618 | Zaffaroni | Jul 1976 | A |
| 3993069 | Buckles et al. | Nov 1976 | A |
| 3993072 | Zaffaroni | Nov 1976 | A |
| 3993073 | Zaffaroni | Nov 1976 | A |
| 4016251 | Higuchi et al. | Apr 1977 | A |
| 4052505 | Higuchi et al. | Oct 1977 | A |
| 4053975 | Olbrich et al. | Oct 1977 | A |
| 4069307 | Higuchi et al. | Jan 1978 | A |
| 4102342 | Akiyama et al. | Jul 1978 | A |
| 4138151 | Nakao | Feb 1979 | A |
| 4184497 | Kolff et al. | Jan 1980 | A |
| 4192317 | Munnerlyn et al. | Mar 1980 | A |
| 4198766 | Camin et al. | Apr 1980 | A |
| 4207890 | Mamajek et al. | Jun 1980 | A |
| 4209919 | Kirikae et al. | Jul 1980 | A |
| 4213095 | Falconer | Jul 1980 | A |
| 4217898 | Theeuwes | Aug 1980 | A |
| 4268115 | Slemon et al. | May 1981 | A |
| 4299226 | Banka | Nov 1981 | A |
| 4299227 | Lincoff | Nov 1981 | A |
| 4306715 | Sutherland | Dec 1981 | A |
| 4312353 | Shahbabian | Jan 1982 | A |
| 4338941 | Payton | Jul 1982 | A |
| D269204 | Trepp | May 1983 | S |
| 4388941 | Reidhammer | Jun 1983 | A |
| RE31351 | Falconer | Aug 1983 | E |
| 4435716 | Zandbergen | Mar 1984 | A |
| 4437856 | Valli | Mar 1984 | A |
| 4450150 | Sidman | May 1984 | A |
| 4459977 | Pizon et al. | Jul 1984 | A |
| 4464175 | Altman et al. | Aug 1984 | A |
| 4471779 | Antoshkiw et al. | Sep 1984 | A |
| 4499899 | Lyons, III | Feb 1985 | A |
| 4554929 | Samson et al. | Nov 1985 | A |
| 4564364 | Zaffaroni et al. | Jan 1986 | A |
| 4571239 | Heyman | Feb 1986 | A |
| 4571240 | Samson et al. | Feb 1986 | A |
| 4581017 | Sahota | Apr 1986 | A |
| 4585000 | Hershenson | Apr 1986 | A |
| D283921 | Dyak | May 1986 | S |
| 4589868 | Dretler | May 1986 | A |
| 4596528 | Lewis et al. | Jun 1986 | A |
| D284892 | Glassman | Jul 1986 | S |
| 4603564 | Kleinhany et al. | Aug 1986 | A |
| 4606346 | Berg et al. | Aug 1986 | A |
| 4607622 | Fritch et al. | Aug 1986 | A |
| 4637389 | Heyden | Jan 1987 | A |
| 4639244 | Rizk et al. | Jan 1987 | A |
| 4645495 | Vaillancourt | Feb 1987 | A |
| 4669469 | Gifford, III | Jun 1987 | A |
| 4672961 | Davies | Jun 1987 | A |
| 4675613 | Naegeli et al. | Jun 1987 | A |
| 4691948 | Austin, Jr. et al. | Sep 1987 | A |
| 4705801 | Martin et al. | Nov 1987 | A |
| 4708434 | Tsuno | Nov 1987 | A |
| 4708834 | Cohen et al. | Nov 1987 | A |
| 4726772 | Amplatz | Feb 1988 | A |
| 4736970 | McGourty et al. | Apr 1988 | A |
| 4737141 | Spits | Apr 1988 | A |
| 4748869 | Ohtsuka | Jun 1988 | A |
| 4748969 | Wardle | Jun 1988 | A |
| 4748986 | Morrison et al. | Jun 1988 | A |
| 4755171 | Tennant | Jul 1988 | A |
| 4771776 | Powell et al. | Sep 1988 | A |
| 4793359 | Sharrow | Dec 1988 | A |
| 4795439 | Guest | Jan 1989 | A |
| 4796629 | Grayzel | Jan 1989 | A |
| 4803076 | Ranade | Feb 1989 | A |
| 4811743 | Stevens | Mar 1989 | A |
| 4815478 | Buchbinder et al. | Mar 1989 | A |
| 4819619 | Augustine et al. | Apr 1989 | A |
| 4846186 | Box et al. | Jul 1989 | A |
| 4847258 | Sturm et al. | Jul 1989 | A |
| 4851228 | Zenter et al. | Jul 1989 | A |
| 4854330 | Evans, III et al. | Aug 1989 | A |
| 4862874 | Kellner | Sep 1989 | A |
| 4867138 | Kubota et al. | Sep 1989 | A |
| 4883465 | Brennan | Nov 1989 | A |
| 4897651 | DeMonte | Jan 1990 | A |
| 4898577 | Badger et al. | Feb 1990 | A |
| 4917419 | Mora, Jr. et al. | Apr 1990 | A |
| 4917667 | Jackson | Apr 1990 | A |
| 4919112 | Siegmund | Apr 1990 | A |
| 4920967 | Cottonaro et al. | May 1990 | A |
| 4925445 | Sakamoto et al. | May 1990 | A |
| 4940062 | Hampton et al. | Jul 1990 | A |
| 4943275 | Stricker | Jul 1990 | A |
| 4946466 | Pinchuk et al. | Aug 1990 | A |
| 4961433 | Christian | Oct 1990 | A |
| 4966163 | Kraus et al. | Oct 1990 | A |
| 4984581 | Stice | Jan 1991 | A |
| 4994033 | Shockey et al. | Feb 1991 | A |
| 4998916 | Hammerslag et al. | Mar 1991 | A |
| 4998917 | Gaiser et al. | Mar 1991 | A |
| 5001825 | Halpern | Mar 1991 | A |
| 5002322 | Fukumoto | Mar 1991 | A |
| 5009655 | Daignault, Jr. et al. | Apr 1991 | A |
| 5019075 | Spears et al. | May 1991 | A |
| 5019372 | Folkman et al. | May 1991 | A |
| 5020514 | Heckele | Jun 1991 | A |
| 5021043 | Becker et al. | Jun 1991 | A |
| 5024650 | Hagiwara et al. | Jun 1991 | A |
| 5024658 | Kozlov et al. | Jun 1991 | A |
| 5026384 | Farr et al. | Jun 1991 | A |
| 5030227 | Rosenbluth et al. | Jul 1991 | A |
| 5041089 | Mueller et al. | Aug 1991 | A |
| 5044678 | Detweiler | Sep 1991 | A |
| 5053007 | Euteneuer | Oct 1991 | A |
| 5055051 | Duncan | Oct 1991 | A |
| 5060660 | Gambale et al. | Oct 1991 | A |
| 5067489 | Lind | Nov 1991 | A |
| 5069226 | Tamauchi et al. | Dec 1991 | A |
| 5087244 | Wolinsky et al. | Feb 1992 | A |
| 5087246 | Smith | Feb 1992 | A |
| 5090595 | Vandeninck | Feb 1992 | A |
| 5090910 | Narlo | Feb 1992 | A |
| 5102402 | Dror et al. | Apr 1992 | A |
| 5112228 | Zouras | May 1992 | A |
| 5116311 | Lofstedt | May 1992 | A |
| 5127393 | McFarlin et al. | Jul 1992 | A |
| 5137517 | Loney et al. | Aug 1992 | A |
| 5139510 | Goldsmith, III et al. | Aug 1992 | A |
| 5139832 | Hayashi et al. | Aug 1992 | A |
| D329496 | Wotton | Sep 1992 | S |
| 5152747 | Oliver | Oct 1992 | A |
| 5156595 | Adams | Oct 1992 | A |
| 5163989 | Campbell et al. | Nov 1992 | A |
| 5167220 | Brown | Dec 1992 | A |
| 5168864 | Shockey | Dec 1992 | A |
| 5169043 | Catania | Dec 1992 | A |
| 5169386 | Becker et al. | Dec 1992 | A |
| 5171233 | Amplatz et al. | Dec 1992 | A |
| 5180368 | Garrison | Jan 1993 | A |
| 5183470 | Wettermann | Feb 1993 | A |
| 5189110 | Ikematu et al. | Feb 1993 | A |
| 5195168 | Yong | Mar 1993 | A |
| 5197457 | Adair | Mar 1993 | A |
| 5207695 | Trout, III | May 1993 | A |
| 5211952 | Spicer et al. | May 1993 | A |
| 5215105 | Kizelshteyn et al. | Jun 1993 | A |
| 5221260 | Burns et al. | Jun 1993 | A |
| 5226302 | Anderson | Jul 1993 | A |
| 5230348 | Ishibe et al. | Jul 1993 | A |
| 5236422 | Eplett, Jr. | Aug 1993 | A |
| 5238004 | Sahatjian et al. | Aug 1993 | A |
| 5243996 | Hall | Sep 1993 | A |
| D340111 | Yoshikawa | Oct 1993 | S |
| 5250059 | Andreas et al. | Oct 1993 | A |
| 5251092 | Brady et al. | Oct 1993 | A |
| 5252183 | Shaban et al. | Oct 1993 | A |
| 5255679 | Imran | Oct 1993 | A |
| 5256144 | Kraus et al. | Oct 1993 | A |
| 5263926 | Wilk | Nov 1993 | A |
| 5264260 | Saab | Nov 1993 | A |
| 5267965 | Deniega | Dec 1993 | A |
| 5269752 | Bennett | Dec 1993 | A |
| 5270086 | Hamlin | Dec 1993 | A |
| 5273052 | Kraus et al. | Dec 1993 | A |
| 5275593 | Easley et al. | Jan 1994 | A |
| 5286254 | Shapland et al. | Feb 1994 | A |
| 5290310 | Makower et al. | Mar 1994 | A |
| 5295694 | Levin | Mar 1994 | A |
| 5300085 | Yock | Apr 1994 | A |
| 5304123 | Atala et al. | Apr 1994 | A |
| 5308326 | Zimmon | May 1994 | A |
| 5312430 | Rosenbluth et al. | May 1994 | A |
| 5313967 | Lieber et al. | May 1994 | A |
| 5314408 | Salmon et al. | May 1994 | A |
| 5314417 | Stephens et al. | May 1994 | A |
| 5315618 | Yoshida | May 1994 | A |
| 5324306 | Makower et al. | Jun 1994 | A |
| 5333620 | Moutafis et al. | Aug 1994 | A |
| 5334167 | Cocanower | Aug 1994 | A |
| 5334187 | Fischell et al. | Aug 1994 | A |
| 5335671 | Clement | Aug 1994 | A |
| 5336163 | DeMane et al. | Aug 1994 | A |
| 5341818 | Abrams et al. | Aug 1994 | A |
| 5342296 | Persson et al. | Aug 1994 | A |
| 5343865 | Gardineer et al. | Sep 1994 | A |
| 5345945 | Hodgson et al. | Sep 1994 | A |
| 5346075 | Nichols et al. | Sep 1994 | A |
| 5346508 | Hastings | Sep 1994 | A |
| 5348537 | Wiesner et al. | Sep 1994 | A |
| 5350396 | Eliachar | Sep 1994 | A |
| 5356418 | Shturman | Oct 1994 | A |
| 5368049 | Raman et al. | Nov 1994 | A |
| 5368558 | Nita | Nov 1994 | A |
| 5368566 | Crocker | Nov 1994 | A |
| 5372138 | Crowley et al. | Dec 1994 | A |
| 5372584 | Zink et al. | Dec 1994 | A |
| D355031 | Yoshikawa | Jan 1995 | S |
| 5386817 | Jones | Feb 1995 | A |
| 5391147 | Imran et al. | Feb 1995 | A |
| 5391179 | Mezzoli | Feb 1995 | A |
| 5402799 | Colon et al. | Apr 1995 | A |
| 5409444 | Kensey | Apr 1995 | A |
| 5411475 | Atala et al. | May 1995 | A |
| 5411476 | Abrams et al. | May 1995 | A |
| 5411477 | Saab | May 1995 | A |
| 5415633 | Lazarus | May 1995 | A |
| 5425370 | Vilkomerson | Jun 1995 | A |
| 5439446 | Barry | Aug 1995 | A |
| 5441494 | Ortiz | Aug 1995 | A |
| 5441497 | Narciso, Jr. | Aug 1995 | A |
| 5445646 | Euteneuer et al. | Aug 1995 | A |
| 5450853 | Hastings et al. | Sep 1995 | A |
| 5451221 | Cho et al. | Sep 1995 | A |
| 5454817 | Katz | Oct 1995 | A |
| 5458572 | Campbell et al. | Oct 1995 | A |
| 5459700 | Jacobs | Oct 1995 | A |
| 5465717 | Imran et al. | Nov 1995 | A |
| 5465733 | Hinohara et al. | Nov 1995 | A |
| 5478565 | Geria | Dec 1995 | A |
| 5486181 | Cohen et al. | Jan 1996 | A |
| 5496338 | Miyagi et al. | Mar 1996 | A |
| 5497783 | Urick et al. | Mar 1996 | A |
| 5507301 | Wasicek et al. | Apr 1996 | A |
| 5507725 | Savage et al. | Apr 1996 | A |
| 5507766 | Kugo et al. | Apr 1996 | A |
| 5507795 | Chiang et al. | Apr 1996 | A |
| 5512055 | Domb et al. | Apr 1996 | A |
| 5514128 | Hillsman et al. | May 1996 | A |
| 5519532 | Broome | May 1996 | A |
| 5531676 | Edwards et al. | Jul 1996 | A |
| 5533985 | Wong | Jul 1996 | A |
| 5538008 | Crowe | Jul 1996 | A |
| 5546964 | Stangerup | Aug 1996 | A |
| 5549542 | Kovalcheck | Aug 1996 | A |
| 5558073 | Pomeranz et al. | Sep 1996 | A |
| 5558652 | Henke | Sep 1996 | A |
| 5562619 | Mirarchi et al. | Oct 1996 | A |
| 5568809 | Ben-Haim | Oct 1996 | A |
| 5571086 | Kaplan et al. | Nov 1996 | A |
| 5578007 | Imran | Nov 1996 | A |
| 5578048 | Pasqualucci et al. | Nov 1996 | A |
| 5582575 | Heckele et al. | Dec 1996 | A |
| 5584827 | Korteweg et al. | Dec 1996 | A |
| 5591194 | Berthiaume | Jan 1997 | A |
| 5599284 | Shea | Feb 1997 | A |
| 5599304 | Shaari | Feb 1997 | A |
| 5599576 | Opolski | Feb 1997 | A |
| 5601087 | Gunderson et al. | Feb 1997 | A |
| 5601594 | Best | Feb 1997 | A |
| 5607386 | Flam | Mar 1997 | A |
| 5617870 | Hastings et al. | Apr 1997 | A |
| 5626374 | Kim | May 1997 | A |
| 5633000 | Grossman et al. | May 1997 | A |
| 5634908 | Loomas | Jun 1997 | A |
| 5638819 | Manwaring et al. | Jun 1997 | A |
| 5643251 | Hillsman et al. | Jul 1997 | A |
| 5645789 | Roucher, Jr. | Jul 1997 | A |
| 5647361 | Damadian | Jul 1997 | A |
| 5656030 | Hunjan et al. | Aug 1997 | A |
| 5662674 | Debbas | Sep 1997 | A |
| 5664567 | Linder | Sep 1997 | A |
| 5664580 | Erickson et al. | Sep 1997 | A |
| 5665052 | Bullard | Sep 1997 | A |
| 5669388 | Vilkomerson | Sep 1997 | A |
| 5673707 | Chandrasekaran | Oct 1997 | A |
| 5676673 | Ferre et al. | Oct 1997 | A |
| 5679400 | Tuch | Oct 1997 | A |
| 5682199 | Lankford | Oct 1997 | A |
| 5685838 | Peters et al. | Nov 1997 | A |
| 5685847 | Barry | Nov 1997 | A |
| 5690373 | Luker | Nov 1997 | A |
| 5693065 | Rains, III | Dec 1997 | A |
| 5694945 | Ben-Haim | Dec 1997 | A |
| 5697159 | Linden | Dec 1997 | A |
| 5700286 | Tartaglia et al. | Dec 1997 | A |
| 5707376 | Kavteladze et al. | Jan 1998 | A |
| 5707389 | Louw et al. | Jan 1998 | A |
| 5708175 | Loyanagi et al. | Jan 1998 | A |
| 5711315 | Jerusalmy | Jan 1998 | A |
| 5713839 | Shea | Feb 1998 | A |
| 5713946 | Ben-Haim | Feb 1998 | A |
| 5718702 | Edwards | Feb 1998 | A |
| 5720300 | Fagan et al. | Feb 1998 | A |
| 5722401 | Pietroski et al. | Mar 1998 | A |
| 5722984 | Fischell et al. | Mar 1998 | A |
| 5729129 | Acker | Mar 1998 | A |
| 5730128 | Pomeranz et al. | Mar 1998 | A |
| 5733248 | Adams et al. | Mar 1998 | A |
| 5752513 | Acker et al. | May 1998 | A |
| 5762604 | Kieturakis | Jun 1998 | A |
| 5766158 | Opolski | Jun 1998 | A |
| 5775327 | Randolph et al. | Jul 1998 | A |
| 5776158 | Chou | Jul 1998 | A |
| 5779699 | Lipson | Jul 1998 | A |
| 5789391 | Jacobus et al. | Aug 1998 | A |
| 5792100 | Shantha | Aug 1998 | A |
| 5797878 | Bleam | Aug 1998 | A |
| 5803089 | Ferre et al. | Sep 1998 | A |
| 5814016 | Valley et al. | Sep 1998 | A |
| 5819723 | Joseph | Oct 1998 | A |
| 5820568 | Willis | Oct 1998 | A |
| 5824044 | Quiachon et al. | Oct 1998 | A |
| 5824048 | Tuch | Oct 1998 | A |
| 5824173 | Fontirroche et al. | Oct 1998 | A |
| 5827224 | Shippert | Oct 1998 | A |
| 5830188 | Abouleish | Nov 1998 | A |
| 5833608 | Acker | Nov 1998 | A |
| 5833645 | Lieber et al. | Nov 1998 | A |
| 5833650 | Imran | Nov 1998 | A |
| 5833682 | Amplatz et al. | Nov 1998 | A |
| 5836638 | Slocum | Nov 1998 | A |
| 5836935 | Ashton et al. | Nov 1998 | A |
| 5837313 | Ding et al. | Nov 1998 | A |
| 5843089 | Sahatjian et al. | Dec 1998 | A |
| 5843113 | High | Dec 1998 | A |
| 5846259 | Berthiaume | Dec 1998 | A |
| 5857998 | Barry | Jan 1999 | A |
| 5862693 | Myers et al. | Jan 1999 | A |
| 5865767 | Frechette et al. | Feb 1999 | A |
| 5872879 | Hamm | Feb 1999 | A |
| 5873835 | Hastings | Feb 1999 | A |
| 5879324 | Von Hoffmann | Mar 1999 | A |
| 5887467 | Butterweck et al. | Mar 1999 | A |
| 5902247 | Coe et al. | May 1999 | A |
| 5902333 | Roberts et al. | May 1999 | A |
| 5904701 | Daneshvar | May 1999 | A |
| 5908407 | Frazee et al. | Jun 1999 | A |
| 5916193 | Stevens et al. | Jun 1999 | A |
| 5928192 | Maahs | Jul 1999 | A |
| 5931811 | Haissaguerre et al. | Aug 1999 | A |
| 5931818 | Werp et al. | Aug 1999 | A |
| 5932035 | Koger et al. | Aug 1999 | A |
| 5935061 | Acker et al. | Aug 1999 | A |
| 5941816 | Barthel et al. | Aug 1999 | A |
| D413629 | Wolff et al. | Sep 1999 | S |
| 5947988 | Smith | Sep 1999 | A |
| 5949929 | Hamm | Sep 1999 | A |
| 5954693 | Barry | Sep 1999 | A |
| 5954694 | Sunseri | Sep 1999 | A |
| 5957842 | Littmann et al. | Sep 1999 | A |
| 5968085 | Morris et al. | Oct 1999 | A |
| 5971975 | Mills et al. | Oct 1999 | A |
| 5979290 | Simeone | Nov 1999 | A |
| 5980503 | Chin | Nov 1999 | A |
| 5980551 | Summers et al. | Nov 1999 | A |
| 5984945 | Sirhan | Nov 1999 | A |
| 5985307 | Hanson et al. | Nov 1999 | A |
| 5997562 | Zadno-Azizi et al. | Dec 1999 | A |
| 6006126 | Cosman | Dec 1999 | A |
| 6006130 | Higo et al. | Dec 1999 | A |
| 6007516 | Burbank et al. | Dec 1999 | A |
| 6007991 | Sivaraman et al. | Dec 1999 | A |
| 6010511 | Murphy | Jan 2000 | A |
| 6013019 | Fischell et al. | Jan 2000 | A |
| 6015414 | Werp et al. | Jan 2000 | A |
| 6016429 | Khafizov et al. | Jan 2000 | A |
| 6016439 | Acker | Jan 2000 | A |
| 6019736 | Avellanet et al. | Feb 2000 | A |
| 6019777 | Mackenzie | Feb 2000 | A |
| 6021340 | Randolph et al. | Feb 2000 | A |
| 6022313 | Ginn et al. | Feb 2000 | A |
| 6027461 | Walker et al. | Feb 2000 | A |
| 6027478 | Katz | Feb 2000 | A |
| 6039699 | Viera | Mar 2000 | A |
| 6042561 | Ash et al. | Mar 2000 | A |
| 6048299 | von Hoffmann | Apr 2000 | A |
| 6048358 | Barak | Apr 2000 | A |
| 6053172 | Hovda et al. | Apr 2000 | A |
| 6056702 | Lorenzo | May 2000 | A |
| 6059752 | Segal | May 2000 | A |
| 6063079 | Hovda et al. | May 2000 | A |
| 6071233 | Ishikawa et al. | Jun 2000 | A |
| 6079755 | Chang | Jun 2000 | A |
| 6080190 | Schwartz | Jun 2000 | A |
| 6083148 | Williams | Jul 2000 | A |
| 6083188 | Becker | Jul 2000 | A |
| 6086585 | Hovda et al. | Jul 2000 | A |
| 6092846 | Fuss et al. | Jul 2000 | A |
| 6093150 | Chandler et al. | Jul 2000 | A |
| 6093195 | Ouchi | Jul 2000 | A |
| 6109268 | Thapliyal et al. | Aug 2000 | A |
| 6113567 | Becker | Sep 2000 | A |
| 6117105 | Bresnaham et al. | Sep 2000 | A |
| 6122541 | Cosman et al. | Sep 2000 | A |
| 6123697 | Shippert | Sep 2000 | A |
| 6135991 | Muni et al. | Oct 2000 | A |
| 6136006 | Johnson et al. | Oct 2000 | A |
| 6139510 | Palermo | Oct 2000 | A |
| 6142957 | Diamond et al. | Nov 2000 | A |
| 6146415 | Fitz | Nov 2000 | A |
| 6148823 | Hastings | Nov 2000 | A |
| 6149213 | Sokurenko et al. | Nov 2000 | A |
| 6159170 | Borodulin et al. | Dec 2000 | A |
| 6171298 | Matsuura et al. | Jan 2001 | B1 |
| 6171303 | Ben-Haim | Jan 2001 | B1 |
| 6174280 | Oneda et al. | Jan 2001 | B1 |
| 6176829 | Vilkomerson | Jan 2001 | B1 |
| 6179788 | Sullivan | Jan 2001 | B1 |
| 6179811 | Fugoso et al. | Jan 2001 | B1 |
| 6183433 | Bays | Feb 2001 | B1 |
| 6183461 | Matsuura et al. | Feb 2001 | B1 |
| 6183464 | Sharp et al. | Feb 2001 | B1 |
| 6190353 | Makower et al. | Feb 2001 | B1 |
| 6190381 | Olsen et al. | Feb 2001 | B1 |
| 6193650 | Ryan, Jr. | Feb 2001 | B1 |
| 6195225 | Komatsu et al. | Feb 2001 | B1 |
| 6200257 | Winkler | Mar 2001 | B1 |
| 6206870 | Kanner | Mar 2001 | B1 |
| 6206900 | Tabatabaei et al. | Mar 2001 | B1 |
| 6213975 | Laksin | Apr 2001 | B1 |
| 6221042 | Adams | Apr 2001 | B1 |
| 6231543 | Hedge et al. | May 2001 | B1 |
| 6234958 | Snoke et al. | May 2001 | B1 |
| 6238364 | Becker | May 2001 | B1 |
| 6238391 | Olsen et al. | May 2001 | B1 |
| 6241519 | Sedlemayer | Jun 2001 | B1 |
| 6249180 | Maalej et al. | Jun 2001 | B1 |
| 6254550 | McNamara et al. | Jul 2001 | B1 |
| 6268574 | Edens | Jul 2001 | B1 |
| 6270477 | Bagaoisan et al. | Aug 2001 | B1 |
| 6290689 | Delaney et al. | Sep 2001 | B1 |
| 6293957 | Peters et al. | Sep 2001 | B1 |
| 6295990 | Lewis et al. | Oct 2001 | B1 |
| 6302875 | Makower et al. | Oct 2001 | B1 |
| 6306105 | Rooney et al. | Oct 2001 | B1 |
| 6306124 | Jones et al. | Oct 2001 | B1 |
| 6308092 | Hoyns | Oct 2001 | B1 |
| D450382 | Nestenborg | Nov 2001 | S |
| 6322495 | Snow et al. | Nov 2001 | B1 |
| 6328564 | Thurow | Dec 2001 | B1 |
| 6332089 | Acker et al. | Dec 2001 | B1 |
| 6332891 | Himes | Dec 2001 | B1 |
| 6340360 | Lyles et al. | Jan 2002 | B1 |
| 6344028 | Barry | Feb 2002 | B1 |
| 6348041 | Klint | Feb 2002 | B1 |
| 6352503 | Matsui et al. | Mar 2002 | B1 |
| 6364856 | Ding et al. | Apr 2002 | B1 |
| 6375615 | Flaherty et al. | Apr 2002 | B1 |
| 6375629 | Muni et al. | Apr 2002 | B1 |
| 6383146 | Klint | May 2002 | B1 |
| 6386197 | Miller | May 2002 | B1 |
| 6389313 | Marchitto et al. | May 2002 | B1 |
| 6390993 | Cornish et al. | May 2002 | B1 |
| 6393312 | Hoyns | May 2002 | B1 |
| 6394093 | Lethi | May 2002 | B1 |
| 6398758 | Jacobsen et al. | Jun 2002 | B1 |
| 6409863 | Williams et al. | Jun 2002 | B1 |
| 6419653 | Edwards et al. | Jul 2002 | B2 |
| 6423012 | Kato et al. | Jul 2002 | B1 |
| 6425877 | Edwards | Jul 2002 | B1 |
| 6432986 | Levin | Aug 2002 | B2 |
| 6440061 | Wenner et al. | Aug 2002 | B1 |
| 6443947 | Marko et al. | Sep 2002 | B1 |
| 6445939 | Swanson et al. | Sep 2002 | B1 |
| 6450975 | Brennan et al. | Sep 2002 | B1 |
| 6450989 | Dubrul et al. | Sep 2002 | B2 |
| 6464650 | Jafari et al. | Oct 2002 | B2 |
| 6468202 | Irion et al. | Oct 2002 | B1 |
| 6468297 | Williams et al. | Oct 2002 | B1 |
| 6485475 | Chelly | Nov 2002 | B1 |
| 6488653 | Lombardo | Dec 2002 | B1 |
| 6491940 | Levin | Dec 2002 | B1 |
| 6494894 | Mirarchi | Dec 2002 | B2 |
| 6500130 | Kinsella et al. | Dec 2002 | B2 |
| 6500189 | Lang et al. | Dec 2002 | B1 |
| 6503087 | Eggert et al. | Jan 2003 | B1 |
| 6503185 | Waksman et al. | Jan 2003 | B1 |
| 6503263 | Adams | Jan 2003 | B2 |
| 6511418 | Shahidi et al. | Jan 2003 | B2 |
| 6514249 | Maguire et al. | Feb 2003 | B1 |
| 6517478 | Khadem | Feb 2003 | B2 |
| 6524129 | Cote et al. | Feb 2003 | B2 |
| 6524299 | Tran et al. | Feb 2003 | B1 |
| 6526302 | Hassett | Feb 2003 | B2 |
| 6527753 | Sekine et al. | Mar 2003 | B2 |
| 6529756 | Phan et al. | Mar 2003 | B1 |
| 6533754 | Hisamatsu et al. | Mar 2003 | B1 |
| 6536437 | Dragisic | Mar 2003 | B1 |
| 6537294 | Boyle et al. | Mar 2003 | B1 |
| 6543452 | Lavigne | Apr 2003 | B1 |
| 6544223 | Kokish | Apr 2003 | B1 |
| 6544230 | Flaherty et al. | Apr 2003 | B1 |
| 6549800 | Atalar et al. | Apr 2003 | B1 |
| 6551239 | Renner et al. | Apr 2003 | B2 |
| 6569146 | Werner et al. | May 2003 | B1 |
| 6569147 | Evans et al. | May 2003 | B1 |
| 6571131 | Nguyen | May 2003 | B1 |
| 6572538 | Takase | Jun 2003 | B2 |
| 6572590 | Stevens et al. | Jun 2003 | B1 |
| 6573984 | Jung et al. | Jun 2003 | B2 |
| 6579285 | Sinofsky | Jun 2003 | B2 |
| 6585639 | Kotmel et al. | Jul 2003 | B1 |
| 6585717 | Wittenberger et al. | Jul 2003 | B1 |
| 6585718 | Hayzelden et al. | Jul 2003 | B2 |
| 6585794 | Shimoda et al. | Jul 2003 | B2 |
| 6589164 | Flaherty | Jul 2003 | B1 |
| 6589237 | Woloszko et al. | Jul 2003 | B2 |
| 6591130 | Shahidi | Jul 2003 | B2 |
| 6596009 | Jelic | Jul 2003 | B1 |
| 6607546 | Murken | Aug 2003 | B1 |
| 6610059 | West, Jr. | Aug 2003 | B1 |
| 6612999 | Brennan et al. | Sep 2003 | B2 |
| 6613066 | Fukaya et al. | Sep 2003 | B1 |
| 6616601 | Hayakawa | Sep 2003 | B2 |
| 6616659 | de la Torre et al. | Sep 2003 | B1 |
| 6616678 | Nishtala et al. | Sep 2003 | B2 |
| 6616913 | Mautone | Sep 2003 | B1 |
| 6619085 | Hsieh | Sep 2003 | B1 |
| 6634684 | Spiessl | Oct 2003 | B2 |
| 6638233 | Corvi et al. | Oct 2003 | B2 |
| 6638268 | Niazi | Oct 2003 | B2 |
| 6638291 | Ferrera et al. | Oct 2003 | B1 |
| 6645193 | Mangosong | Nov 2003 | B2 |
| 6652472 | Jafari et al. | Nov 2003 | B2 |
| 6652480 | Imran et al. | Nov 2003 | B1 |
| 6656166 | Lurie et al. | Dec 2003 | B2 |
| 6659106 | Hovda et al. | Dec 2003 | B1 |
| 6663589 | Halevy | Dec 2003 | B1 |
| 6669689 | Lehmann et al. | Dec 2003 | B2 |
| 6669711 | Noda | Dec 2003 | B1 |
| 6672773 | Glenn et al. | Jan 2004 | B1 |
| 6673025 | Richardson et al. | Jan 2004 | B1 |
| 6679871 | Hahnen | Jan 2004 | B2 |
| 6685648 | Flaherty et al. | Feb 2004 | B2 |
| 6689096 | Loubens et al. | Feb 2004 | B1 |
| 6689146 | Himes | Feb 2004 | B1 |
| 6702735 | Kelly | Mar 2004 | B2 |
| 6712757 | Becker et al. | Mar 2004 | B2 |
| 6714809 | Lee et al. | Mar 2004 | B2 |
| 6716183 | Clayman et al. | Apr 2004 | B2 |
| 6716216 | Boucher et al. | Apr 2004 | B1 |
| 6716813 | Lim et al. | Apr 2004 | B2 |
| 6719749 | Schweikert et al. | Apr 2004 | B1 |
| 6719763 | Chung et al. | Apr 2004 | B2 |
| 6726701 | Gilson et al. | Apr 2004 | B2 |
| 6738656 | Ferre et al. | May 2004 | B1 |
| 6755812 | Peterson et al. | Jun 2004 | B2 |
| 6776772 | de Vrijer et al. | Aug 2004 | B1 |
| 6780168 | Jellie | Aug 2004 | B2 |
| 6783522 | Fischell | Aug 2004 | B2 |
| 6783536 | Vilsmeier et al. | Aug 2004 | B2 |
| 6786864 | Matsuura et al. | Sep 2004 | B2 |
| 6796960 | Cioanta et al. | Sep 2004 | B2 |
| 6811544 | Schaer | Nov 2004 | B2 |
| 6817364 | Garibaldi et al. | Nov 2004 | B2 |
| 6817976 | Rovegno | Nov 2004 | B2 |
| 6827683 | Otawara | Dec 2004 | B2 |
| 6827701 | MacMahon et al. | Dec 2004 | B2 |
| 6832715 | Eungard et al. | Dec 2004 | B2 |
| D501677 | Becker | Feb 2005 | S |
| 6851290 | Meier et al. | Feb 2005 | B1 |
| 6855136 | Dorros et al. | Feb 2005 | B2 |
| 6860264 | Christopher | Mar 2005 | B2 |
| 6860849 | Matsushita et al. | Mar 2005 | B2 |
| 6878106 | Herrmann | Apr 2005 | B1 |
| 6890329 | Carroll et al. | May 2005 | B2 |
| 6899672 | Chin et al. | May 2005 | B2 |
| 6902556 | Grimes et al. | Jun 2005 | B2 |
| 6913763 | Lerner | Jul 2005 | B2 |
| 6927478 | Paek | Aug 2005 | B2 |
| 6939361 | Kleshinski | Sep 2005 | B1 |
| 6939374 | Banik et al. | Sep 2005 | B2 |
| 6955657 | Webler | Oct 2005 | B1 |
| 6966906 | Brown | Nov 2005 | B2 |
| 6971998 | Rosenman et al. | Dec 2005 | B2 |
| 6979290 | Mourlas et al. | Dec 2005 | B2 |
| 6984203 | Tartaglia et al. | Jan 2006 | B2 |
| 6991597 | Gellman et al. | Jan 2006 | B2 |
| 6997931 | Sauer et al. | Feb 2006 | B2 |
| 6997941 | Sharkey et al. | Feb 2006 | B2 |
| 7004173 | Sparks et al. | Feb 2006 | B2 |
| 7008412 | Maginot | Mar 2006 | B2 |
| 7022105 | Edwards | Apr 2006 | B1 |
| 7043961 | Pandey | May 2006 | B2 |
| 7044964 | Jang et al. | May 2006 | B2 |
| 7052474 | Castell et al. | May 2006 | B2 |
| 7056284 | Martone et al. | Jun 2006 | B2 |
| 7056303 | Dennis et al. | Jun 2006 | B2 |
| 7074197 | Reynolds et al. | Jul 2006 | B2 |
| 7074426 | Kochinke | Jul 2006 | B2 |
| 7077836 | Lary et al. | Jul 2006 | B2 |
| 7097612 | Bertolero et al. | Aug 2006 | B2 |
| 7108677 | Courtney et al. | Sep 2006 | B2 |
| 7108706 | Hogle | Sep 2006 | B2 |
| 7128718 | Hojeibane et al. | Oct 2006 | B2 |
| 7131969 | Hovda et al. | Nov 2006 | B1 |
| 7140480 | Drussel et al. | Nov 2006 | B2 |
| D534215 | Nakata | Dec 2006 | S |
| 7160255 | Saadat | Jan 2007 | B2 |
| 7169140 | Kume | Jan 2007 | B1 |
| 7172562 | McKinley | Feb 2007 | B2 |
| 7174774 | Pawar et al. | Feb 2007 | B2 |
| 7182735 | Shireman et al. | Feb 2007 | B2 |
| 7184827 | Edwards | Feb 2007 | B1 |
| 7207981 | Quinn et al. | Apr 2007 | B2 |
| 7214201 | Burmeister et al. | May 2007 | B2 |
| 7233820 | Gilboa | Jun 2007 | B2 |
| 7235099 | Duncavage et al. | Jun 2007 | B1 |
| 7237313 | Skujins et al. | Jul 2007 | B2 |
| 7252677 | Burwell et al. | Aug 2007 | B2 |
| 7282057 | Surti et al. | Oct 2007 | B2 |
| 7294345 | Haapakumpu et al. | Nov 2007 | B2 |
| 7294365 | Hayakawa et al. | Nov 2007 | B2 |
| 7303533 | Johansen et al. | Dec 2007 | B2 |
| 7313430 | Urquhart et al. | Dec 2007 | B2 |
| 7316168 | van der Knokke et al. | Jan 2008 | B2 |
| 7316656 | Shireman et al. | Jan 2008 | B2 |
| 7318831 | Alvarez et al. | Jan 2008 | B2 |
| 7322934 | Miyake et al. | Jan 2008 | B2 |
| 7326235 | Edwards | Feb 2008 | B2 |
| 7338467 | Lutter | Mar 2008 | B2 |
| 7343920 | Toby et al. | Mar 2008 | B2 |
| 7359755 | Jones et al. | Apr 2008 | B2 |
| 7366562 | Dukesherer | Apr 2008 | B2 |
| 7371210 | Brock et al. | May 2008 | B2 |
| 7381205 | Thommen | Jun 2008 | B2 |
| 7410480 | Muni et al. | Aug 2008 | B2 |
| 7419497 | Muni et al. | Sep 2008 | B2 |
| 7438701 | Theeuwes et al. | Oct 2008 | B2 |
| 7452351 | Miller et al. | Nov 2008 | B2 |
| 7462175 | Chang et al. | Dec 2008 | B2 |
| 7471994 | Ford et al. | Dec 2008 | B2 |
| 7481218 | Djupesland | Jan 2009 | B2 |
| 7481800 | Jacques | Jan 2009 | B2 |
| D586465 | Faulkner et al. | Feb 2009 | S |
| D586916 | Faulkner et al. | Feb 2009 | S |
| 7488313 | Segal et al. | Feb 2009 | B2 |
| 7488337 | Saab et al. | Feb 2009 | B2 |
| 7493156 | Manning et al. | Feb 2009 | B2 |
| D590502 | Geisser et al. | Apr 2009 | S |
| 7532920 | Ainsworth et al. | May 2009 | B1 |
| 7544192 | Eaton et al. | Jun 2009 | B2 |
| 7610104 | Kaplan et al. | Oct 2009 | B2 |
| 7615005 | Stefanchik et al. | Nov 2009 | B2 |
| 7618450 | Zarowski et al. | Nov 2009 | B2 |
| 7625335 | Deichmann et al. | Dec 2009 | B2 |
| 7632291 | Stephens et al. | Dec 2009 | B2 |
| 7634233 | Deng et al. | Dec 2009 | B2 |
| 7641644 | Chang et al. | Jan 2010 | B2 |
| 7641668 | Perry et al. | Jan 2010 | B2 |
| 7648367 | Makower et al. | Jan 2010 | B1 |
| 7680244 | Gertner et al. | Mar 2010 | B2 |
| 7686798 | Eaton et al. | Mar 2010 | B2 |
| 7691120 | Shluzas et al. | Apr 2010 | B2 |
| 7727186 | Makower et al. | Jun 2010 | B2 |
| 7727226 | Chang et al. | Jun 2010 | B2 |
| 7736301 | Webler et al. | Jun 2010 | B1 |
| 7740642 | Becker | Jun 2010 | B2 |
| 7753929 | Becker | Jul 2010 | B2 |
| 7753930 | Becker | Jul 2010 | B2 |
| 7771409 | Chang et al. | Aug 2010 | B2 |
| 7775968 | Mathis | Aug 2010 | B2 |
| 7785315 | Muni et al. | Aug 2010 | B1 |
| 7799048 | Hudson et al. | Sep 2010 | B2 |
| 7799337 | Levin | Sep 2010 | B2 |
| 7833282 | Mandpe | Nov 2010 | B2 |
| 7837672 | Intoccia | Nov 2010 | B2 |
| 7840254 | Glossop | Nov 2010 | B2 |
| 7854744 | Becker | Dec 2010 | B2 |
| D630321 | Hamilton, Jr. | Jan 2011 | S |
| 7875050 | Samson et al. | Jan 2011 | B2 |
| D632791 | Murner | Feb 2011 | S |
| 7881769 | Sobe | Feb 2011 | B2 |
| 7883717 | Varner et al. | Feb 2011 | B2 |
| 7896891 | Catanese, III et al. | Mar 2011 | B2 |
| 7951132 | Eaton et al. | May 2011 | B2 |
| 7988705 | Galdonik et al. | Aug 2011 | B2 |
| 7993353 | Roβner et al. | Aug 2011 | B2 |
| 8002740 | Willink et al. | Aug 2011 | B2 |
| 8014849 | Peckham | Sep 2011 | B2 |
| 8016752 | Armstrong et al. | Sep 2011 | B2 |
| 8025635 | Eaton et al. | Sep 2011 | B2 |
| 8080000 | Makower et al. | Dec 2011 | B2 |
| 8088063 | Fujikura et al. | Jan 2012 | B2 |
| 8088101 | Chang et al. | Jan 2012 | B2 |
| 8090433 | Makower et al. | Jan 2012 | B2 |
| 8100933 | Becker | Jan 2012 | B2 |
| 8104483 | Taylor | Jan 2012 | B2 |
| 8114062 | Muni et al. | Feb 2012 | B2 |
| 8114113 | Becker | Feb 2012 | B2 |
| 8123722 | Chang et al. | Feb 2012 | B2 |
| 8142422 | Makower et al. | Mar 2012 | B2 |
| 8146400 | Goldfarb et al. | Apr 2012 | B2 |
| 8147545 | Avior | Apr 2012 | B2 |
| 8167821 | Sharrow | May 2012 | B2 |
| 8172828 | Chang et al. | May 2012 | B2 |
| 8190389 | Kim et al. | May 2012 | B2 |
| 8197433 | Cohen | Jun 2012 | B2 |
| 8197552 | Mandpe | Jun 2012 | B2 |
| 8249700 | Clifford et al. | Aug 2012 | B2 |
| 8277386 | Ahmed et al. | Oct 2012 | B2 |
| 8337454 | Eaton et al. | Dec 2012 | B2 |
| 8388642 | Muni et al. | Mar 2013 | B2 |
| 8403954 | Santin et al. | Mar 2013 | B2 |
| 8414473 | Jenkins et al. | Apr 2013 | B2 |
| 8425457 | John et al. | Apr 2013 | B2 |
| 8439687 | Morriss et al. | May 2013 | B1 |
| 8535707 | Arensdorf et al. | Sep 2013 | B2 |
| 8702626 | Kim et al. | Apr 2014 | B1 |
| 8777926 | Chang et al. | Jul 2014 | B2 |
| 20010004644 | Levin | Jun 2001 | A1 |
| 20010005785 | Sachse | Jun 2001 | A1 |
| 20010027307 | Dubrul et al. | Oct 2001 | A1 |
| 20010034530 | Malackowski et al. | Oct 2001 | A1 |
| 20020006961 | Katz et al. | Jan 2002 | A1 |
| 20020055746 | Burke et al. | May 2002 | A1 |
| 20020077593 | Perkins et al. | Jun 2002 | A1 |
| 20020090388 | Humes et al. | Jul 2002 | A1 |
| 20020165521 | Cioanta et al. | Nov 2002 | A1 |
| 20030013985 | Saadat | Jan 2003 | A1 |
| 20030017111 | Rabito | Jan 2003 | A1 |
| 20030018291 | Hill et al. | Jan 2003 | A1 |
| 20030040697 | Pass et al. | Feb 2003 | A1 |
| 20030073900 | Senarith et al. | Apr 2003 | A1 |
| 20030083608 | Evans et al. | May 2003 | A1 |
| 20030114732 | Webler et al. | Jun 2003 | A1 |
| 20030163154 | Miyata et al. | Aug 2003 | A1 |
| 20030208194 | Hovda et al. | Nov 2003 | A1 |
| 20030220551 | Kimball et al. | Nov 2003 | A1 |
| 20040015150 | Zadno-Azizi | Jan 2004 | A1 |
| 20040018980 | Gurney et al. | Jan 2004 | A1 |
| 20040020492 | Dubrul et al. | Feb 2004 | A1 |
| 20040034311 | Mihakcik | Feb 2004 | A1 |
| 20040043052 | Hunter et al. | Mar 2004 | A1 |
| 20040058992 | Marinello et al. | Mar 2004 | A1 |
| 20040064083 | Becker | Apr 2004 | A1 |
| 20040064105 | Capes et al. | Apr 2004 | A1 |
| 20040064150 | Becker | Apr 2004 | A1 |
| 20040116958 | Gopferich et al. | Jun 2004 | A1 |
| 20040127820 | Clayman et al. | Jul 2004 | A1 |
| 20040158229 | Quinn | Aug 2004 | A1 |
| 20040181175 | Clayman et al. | Sep 2004 | A1 |
| 20040193073 | DeMello et al. | Sep 2004 | A1 |
| 20040230131 | Kassab et al. | Nov 2004 | A1 |
| 20040230156 | Schreck et al. | Nov 2004 | A1 |
| 20040236231 | Knighton et al. | Nov 2004 | A1 |
| 20040249243 | Kleiner | Dec 2004 | A1 |
| 20040267347 | Cervantes | Dec 2004 | A1 |
| 20050027249 | Reifart et al. | Feb 2005 | A1 |
| 20050055077 | Marco | Mar 2005 | A1 |
| 20050059930 | Garrison et al. | Mar 2005 | A1 |
| 20050059931 | Garrison et al. | Mar 2005 | A1 |
| 20050089670 | Large | Apr 2005 | A1 |
| 20050107738 | Slater et al. | May 2005 | A1 |
| 20050113687 | Herweck et al. | May 2005 | A1 |
| 20050113850 | Tagge | May 2005 | A1 |
| 20050119590 | Burmeister et al. | Jun 2005 | A1 |
| 20050131316 | Flagle et al. | Jun 2005 | A1 |
| 20050137459 | Chin et al. | Jun 2005 | A1 |
| 20050143687 | Rosenblatt et al. | Jun 2005 | A1 |
| 20050182319 | Glossop | Aug 2005 | A1 |
| 20050234507 | Geske et al. | Oct 2005 | A1 |
| 20050240147 | Makower et al. | Oct 2005 | A1 |
| 20050244472 | Hughes et al. | Nov 2005 | A1 |
| 20050245906 | Makower et al. | Nov 2005 | A1 |
| 20050283221 | Mann et al. | Dec 2005 | A1 |
| 20060004286 | Chang et al. | Jan 2006 | A1 |
| 20060004323 | Chang et al. | Jan 2006 | A1 |
| 20060047261 | Joshi | Mar 2006 | A1 |
| 20060063973 | Makower et al. | Mar 2006 | A1 |
| 20060149310 | Becker | Jul 2006 | A1 |
| 20060173382 | Schreiner | Aug 2006 | A1 |
| 20060189844 | Tien | Aug 2006 | A1 |
| 20060190022 | Beyar et al. | Aug 2006 | A1 |
| 20060210605 | Chang et al. | Sep 2006 | A1 |
| 20060211752 | Kohn et al. | Sep 2006 | A1 |
| 20060271024 | Gertner et al. | Nov 2006 | A1 |
| 20060284428 | Beadle et al. | Dec 2006 | A1 |
| 20070020196 | Pipkin et al. | Jan 2007 | A1 |
| 20070112358 | Abbott | May 2007 | A1 |
| 20070129751 | Muni et al. | Jun 2007 | A1 |
| 20070135789 | Chang et al. | Jun 2007 | A1 |
| 20070167682 | Goldfarb et al. | Jul 2007 | A1 |
| 20070207186 | Scanlon et al. | Sep 2007 | A1 |
| 20070208252 | Makower | Sep 2007 | A1 |
| 20070208301 | Evard et al. | Sep 2007 | A1 |
| 20070249896 | Goldfarb et al. | Oct 2007 | A1 |
| 20070250105 | Ressemann et al. | Oct 2007 | A1 |
| 20070269385 | Yun et al. | Nov 2007 | A1 |
| 20070282305 | Goldfarb et al. | Dec 2007 | A1 |
| 20070293727 | Goldfarb et al. | Dec 2007 | A1 |
| 20070293946 | Gonzales et al. | Dec 2007 | A1 |
| 20080015544 | Keith et al. | Jan 2008 | A1 |
| 20080033519 | Burwell et al. | Feb 2008 | A1 |
| 20080051804 | Cottler et al. | Feb 2008 | A1 |
| 20080082045 | Goldfarb et al. | Apr 2008 | A1 |
| 20080097400 | Chang et al. | Apr 2008 | A1 |
| 20080097515 | Chang et al. | Apr 2008 | A1 |
| 20080097516 | Chang et al. | Apr 2008 | A1 |
| 20080103521 | Makower et al. | May 2008 | A1 |
| 20080119693 | Makower et al. | May 2008 | A1 |
| 20080125626 | Chang et al. | May 2008 | A1 |
| 20080132938 | Chang et al. | Jun 2008 | A1 |
| 20080172033 | Keith et al. | Jul 2008 | A1 |
| 20080183128 | Morriss et al. | Jul 2008 | A1 |
| 20080188803 | Jang | Aug 2008 | A1 |
| 20080188870 | Andre et al. | Aug 2008 | A1 |
| 20080195041 | Goldfarb et al. | Aug 2008 | A1 |
| 20080214959 | Miyata et al. | Sep 2008 | A1 |
| 20080228085 | Jenkins et al. | Sep 2008 | A1 |
| 20080262508 | Clifford et al. | Oct 2008 | A1 |
| 20080275483 | Makower et al. | Nov 2008 | A1 |
| 20080281156 | Makower et al. | Nov 2008 | A1 |
| 20080287908 | Muni et al. | Nov 2008 | A1 |
| 20080319424 | Muni et al. | Dec 2008 | A1 |
| 20090030274 | Goldfarb et al. | Jan 2009 | A1 |
| 20090030409 | Goldfarb et al. | Jan 2009 | A1 |
| 20090088728 | Dollar et al. | Apr 2009 | A1 |
| 20090156980 | Eaton et al. | Jun 2009 | A1 |
| 20090163890 | Clifford et al. | Jun 2009 | A1 |
| 20090187089 | Say et al. | Jul 2009 | A1 |
| 20090198216 | Muni et al. | Aug 2009 | A1 |
| 20090240112 | Goldfarb et al. | Sep 2009 | A1 |
| 20090240237 | Goldfarb et al. | Sep 2009 | A1 |
| 20090312745 | Goldfarb et al. | Dec 2009 | A1 |
| 20100030031 | Goldfarb et al. | Feb 2010 | A1 |
| 20100042046 | Chang et al. | Feb 2010 | A1 |
| 20100087811 | Herrin et al. | Apr 2010 | A1 |
| 20100114066 | Makower et al. | May 2010 | A1 |
| 20100174138 | Chang et al. | Jul 2010 | A1 |
| 20100174308 | Chang et al. | Jul 2010 | A1 |
| 20100198191 | Clifford et al. | Aug 2010 | A1 |
| 20100198247 | Chang et al. | Aug 2010 | A1 |
| 20100198302 | Shalev | Aug 2010 | A1 |
| 20100210901 | Makower et al. | Aug 2010 | A1 |
| 20100268245 | Chang et al. | Oct 2010 | A1 |
| 20100274188 | Chang et al. | Oct 2010 | A1 |
| 20100290244 | Nath | Nov 2010 | A1 |
| 20100298862 | Chang et al. | Nov 2010 | A1 |
| 20110004057 | Goldfarb et al. | Jan 2011 | A1 |
| 20110015482 | Carrillo, Jr. | Jan 2011 | A1 |
| 20110060214 | Makower | Mar 2011 | A1 |
| 20110112512 | Muni et al. | May 2011 | A1 |
| 20110166190 | Anderson et al. | Jul 2011 | A1 |
| 20120071710 | Gazdzinski | Mar 2012 | A1 |
| 20120071824 | Chang et al. | Mar 2012 | A1 |
| 20120136207 | Goldfarb et al. | May 2012 | A1 |
| 20120184983 | Chang et al. | Jul 2012 | A1 |
| 20120245419 | Makower et al. | Sep 2012 | A1 |
| 20120265094 | Goldfarb et al. | Oct 2012 | A1 |
| 20130231529 | John et al. | Sep 2013 | A1 |
| 20130245608 | Muni et al. | Sep 2013 | A1 |
| 20130261388 | Jenkins et al. | Oct 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 2013323 | Sep 1990 | CA |
| 668188 | Dec 1988 | CH |
| 2151720 | Jan 1994 | CN |
| 2352818 | Dec 1999 | CN |
| 101766469 | Jul 2010 | CN |
| 3202878 | Aug 1983 | DE |
| 4032096 | Apr 1992 | DE |
| 4406077 | Sep 1994 | DE |
| 19707740 | Sep 1998 | DE |
| 8810044 | Nov 1998 | DE |
| 10104663 | Aug 2002 | DE |
| 10105592 | Aug 2002 | DE |
| 129634 | Jan 1985 | EP |
| 0200430 | Nov 1986 | EP |
| 257605 | Mar 1988 | EP |
| 355996 | Feb 1990 | EP |
| 418391 | Mar 1991 | EP |
| 427852 | May 1991 | EP |
| 0515201 | Nov 1992 | EP |
| 623582 | Nov 1994 | EP |
| 624349 | Nov 1994 | EP |
| 744400 | Nov 1996 | EP |
| 585757 | Jun 1997 | EP |
| 893426 | Jan 1999 | EP |
| 0920882 | Jun 1999 | EP |
| 0974936 | Jan 2000 | EP |
| 1042998 | Oct 2000 | EP |
| 1086664 | Mar 2001 | EP |
| 1166710 | Jan 2002 | EP |
| 1413258 | Apr 2004 | EP |
| 1944053 | Jul 2008 | EP |
| 2859377 | Mar 2005 | FR |
| 2916144 | Nov 2008 | FR |
| 2125874 | Mar 1984 | GB |
| 2305174 | Apr 1997 | GB |
| 10-24098 | Jan 1989 | JP |
| 4-221313 | Aug 1992 | JP |
| 6-277296 | Oct 1994 | JP |
| 8-317989 | Dec 1996 | JP |
| 2001-501846 | Feb 2001 | JP |
| 2001-095815 | Apr 2001 | JP |
| 2001-526077 | Dec 2001 | JP |
| 2002-028166 | Jan 2002 | JP |
| 2002-508214 | Mar 2002 | JP |
| 2002-537908 | Nov 2002 | JP |
| 2002-538850 | Nov 2002 | JP |
| 2003-507140 | Feb 2003 | JP |
| 2003-521327 | Jul 2003 | JP |
| 2004-357728 | Dec 2004 | JP |
| 2005-532869 | Nov 2005 | JP |
| 2213530 | Oct 2003 | RU |
| WO 9011053 | Oct 1990 | WO |
| WO 9014865 | Dec 1990 | WO |
| WO 9117787 | Nov 1991 | WO |
| WO 9215286 | Sep 1992 | WO |
| WO 9222350 | Dec 1992 | WO |
| WO 9412095 | Jun 1994 | WO |
| WO 9421320 | Sep 1994 | WO |
| WO 9502430 | Jan 1995 | WO |
| WO 9629071 | Sep 1996 | WO |
| WO 9721461 | Jun 1997 | WO |
| WO 9855174 | Dec 1998 | WO |
| WO 9900064 | Jan 1999 | WO |
| WO 9924106 | May 1999 | WO |
| WO 9926692 | Jun 1999 | WO |
| WO 9930655 | Jun 1999 | WO |
| WO 9932041 | Jul 1999 | WO |
| WO 9959649 | Nov 1999 | WO |
| WO 0009190 | Feb 2000 | WO |
| WO 0009192 | Feb 2000 | WO |
| WO 0023009 | Apr 2000 | WO |
| WO 0051672 | Sep 2000 | WO |
| WO 0053252 | Sep 2000 | WO |
| WO 0105462 | Jan 2001 | WO |
| WO 0145572 | Jun 2001 | WO |
| WO 0154558 | Aug 2001 | WO |
| WO 0156481 | Aug 2001 | WO |
| WO 0170325 | Sep 2001 | WO |
| WO 0174266 | Oct 2001 | WO |
| WO 0197895 | Dec 2001 | WO |
| WO 02062269 | Aug 2002 | WO |
| WO 02089899 | Nov 2002 | WO |
| WO 03049603 | Jun 2003 | WO |
| WO 03063703 | Aug 2003 | WO |
| WO 03105657 | Dec 2003 | WO |
| WO 2004006788 | Jan 2004 | WO |
| WO 2004018980 | Mar 2004 | WO |
| WO 2004026391 | Apr 2004 | WO |
| WO 2004082525 | Sep 2004 | WO |
| WO 2004082525 | Sep 2004 | WO |
| WO 2005018730 | Mar 2005 | WO |
| WO 2005077450 | Aug 2005 | WO |
| WO 2005089670 | Sep 2005 | WO |
| WO 2005117755 | Dec 2005 | WO |
| WO 2006034008 | Mar 2006 | WO |
| WO 2006078884 | Jul 2006 | WO |
| WO 2006107957 | Oct 2006 | WO |
| WO 2006116597 | Nov 2006 | WO |
| WO 2006118737 | Nov 2006 | WO |
| WO 2006135853 | Dec 2006 | WO |
| WO 2008036149 | Mar 2007 | WO |
| WO 2007111636 | Oct 2007 | WO |
| WO 2007124260 | Nov 2007 | WO |
| WO 2008045242 | Apr 2008 | WO |
| WO 2008051918 | May 2008 | WO |
| WO 2008134382 | Nov 2008 | WO |
| Entry |
|---|
| Argon Medical, Maxxim Medical, Ad for Sniper EliteTM Hydrophilic Ni—Ti Alloy Guidewire (2001). |
| Aust, R., et al. ‘The Functional Size of the Human Maxillary Ostium In Vivo’ Acta. Otolaryn. (9178) vol. 78 pp. 432-435. |
| Baim, D.S., MD ‘Grossman's Cardiac Catherization, Angiography, and Intervention’ (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214. |
| Barrett, S. ‘Be Wary of Neurocranial Restructuring (NCR)’ Chirobase; Jul. 2003; www.chirobase.org/06DD/ncr.html. |
| Bartal, N. ‘An Improved stent for Use in the Surgical Management of Congential Posterior Choanal Atresia’ J. Laryngol. Otol (1988) vol. 102 pp. 146-147. |
| Becker, A.E. ‘Restenosis After Angioplasty’ The Lancet (1988) vol. 331, No. 8584 p. 532. |
| Bellis, M. History of the Catheter—Balloon Catheter—Thomas Fogarty, Www.inventors.about.com/library/inventors/blcatheter.htm?p=1. |
| Benninger et al.; Adult Chronic Rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysilogy' Arch Otolarygol Head and Neck Surg. vol. 129 (Sep. 2003) pp. A1-S32. |
| Bent et al. The Frontal Cell as a Cause of Frontal Sinus Obstruction American Journal of Rhinology, vol. 8, No. 4 (1994) pp. 185-191. |
| Binner et al. ‘Fibre-Optic Transillunination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease’ Clinical Otolaryngology. vol. 3 (1978) pp. 1-11. |
| Brown, C.L. et al., ‘Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation’ Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299. |
| Casiano et al. ‘Endoscopic Lothrop Procedure: the University of Miami Experience’ American Journal of Rhinology, vol. 12, No. 5 (1998) pp. 335-339. |
| Casserly, I.P. et al., Chapter 7. ‘Guides and Wires in Percutaneous Coronary Intervention’ Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99. |
| Chien, Y.W. et al. ‘Nasal Systemic Drug Delivery’ Drugs and Pharmaceutical Sciences, vol. 39, pp. 60-63. |
| Cohen et al. ‘Endoscopic Sinus Surgery: Where we are and where we're going’ Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 13 (2005) pp. 32-38. |
| Colla, A. et al., ‘Trihaloacetylated Enol Ethers—General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine’ Synthesis, (Jun. 1991) pp. 483-486. |
| Costa, M.N. et al. ‘Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5-Flurorouracil’ Clinics (2007) vol. 62, Issue 1, pp. 41-46. |
| Cussler, E.L. ‘Diffusion: Mass transfer in Fluid Systems’ Cambridge University Press (1996). |
| Davis, G.E. et al. ‘A Complication from Neurocranial Restructuring’ Arch Otolaryngol Head Neck Surg. vol. 129 (Apr. 2003) pp. 472-474. |
| Domb, A. et al. ‘Handbook of Biodegradable Polymers’ Harwood Academic Publishers (1997). |
| Doyle Nasal Splints, Jan. 25, 2007; www.doylemedical.com/nasalsplints.htm. |
| Draf, W. ‘Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept’Op Tech Otolaryngol Head Neck Surg. vol. 2 (1991) pp. 234-240. |
| Edmond, C. et al. ‘ENT Surgical Stimulator’ Nov. 1989. |
| ENT Checklist; Physical Examination Performance Checklist [date of publication unknown]. |
| Eremychev, V.A. ‘Needles for Puncture and Drainage of the Maxillary Sinus’ Meditsinskaya Tekhnika, No. 5 (1974) pp. 54,55. |
| Feldman, R.L. et al., ‘New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis OrionTM Steerable PTCA Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145. |
| Ford, C.N. ‘A Multipurpose Laryngeal Injector Device’ Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137. |
| Friedman, M., M.D., et al. ‘Frontal Sinus Surgery: Endoscopic Technique’ Operative Techniques in Otolarynology—Head and Neck Surgery, vol. 12, No. 2 (Jun. 2001) pp. 60-65. |
| Friedman, et al. ‘Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination’ Laryngoscope, vol. 110 (Apr. 2000) pp. 683-684. |
| Freidman, et al ‘Middle Turbinate Medialization and Preservation in Endoscopic Surgery’ Otolaryngology—Head and Neck Surgery, (2000) vol. 123, No. 1, part 1, pp. 76-80. |
| Fung, M.K.T. ‘Template for Frontal Osteoplastic Flap’ Laryngoscope. vol. 96 (1986) pp. 578-579. |
| Gatot, A. et al. ‘Early treatment of Orbital Floor Fractures with Catheter Balloon in Children’ Int J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101. |
| Gerus, I.I. et al. ‘β-Ethoxyvinyl Polyfluroralkyl Ketones—Versatile Synthones in Fluoroorganic Chemistry’ Journal of Fluorine Chemistry. vol. 69 (1994) pp. 195-198. Elsevier Science S.A. |
| Good, R.H. ‘An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage’ Laryngoscope, vol. 18 (1908) pp. 266-274. |
| Gopferich ‘Polymer Degradation and Erosion: Mechanisms and Application’ Eur. J. Parm. Biophar. vol. 42 (1996) pp. 1-11. |
| Gorlov, D.V. et al ‘Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence ot Teriary Amines’ Russian Chemical Bulletin. vol. 48 No. 9 (Sep. 1999) pp. 1791-1792. Kluwer Academic/Plenum Publishers. |
| Gottmann, et al. ‘Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses’ CIRSE. (Sep. 25, 2004) pp. 1-27. |
| Gottmann, et al. ‘Balloon Dilatation of Recurrent Ostial Occlusion of the Frontal Sinus’ CIRSE Abstract (Mar. 2001) B-04353. |
| Gottmann, et al., Balloon Dilatation of Recurrent Ostial Occlusion of the Frontal Sinus OASIS—Online Abstract Submission and Invitation System, 1996-2006, Coe Truman Technologies, Inc. |
| Gottmann, et al. ‘Successful Treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation’ CIRSE. (Oct. 5, 2002). |
| Gottmann, D. ‘Treatment of Stenoses of Upper Air Routes by Balloon Dilatation’ Proceeding of the 83rd Annual Convention of Association of West German ENT Physicians (1999). |
| Gupta, D. et al., ‘Dacrystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus’ Ear, Nose & Throat Journal (2009) www.findarticles.com/p/articles/mi—m0BUM/is—7—88/ai—n32428620/. |
| Hashim, et al. ‘Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery’ Scandinavian Journal of Plastic and reconstruction Sergery and Hand Surgery (1999) vol. 22 pp. 321-324. |
| Hojo, M. et al, ‘Electrophilic Substiutions of Olefinic Hydrogens II. Acylation of Vinyle Ethers and N Vinyl Amides Chemistry Letters’ (1976) pp. 499-502. Chemical Society of Japan. |
| Hopf, J.U.G. et al. ‘Minature Endoscopes in Otorhinolaryngologic Applications’ Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218. |
| Hosemann, W. et al. A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37. |
| Hosemann, W. et al. ‘Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation’ American Journal of Rhinology. vol. 11, No. 1 (1997) pp. 1-9. |
| Hosemann, M.E. et al.‘Experimentelle Untersuchungen sur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss und medikamentose Effekte im standardisierten Wundmodell.’ HNO 39 (1991) pp. 48-54. ‘Experimental investigations on wound healing of the paranasal sinuses. II. Spontaneous wound closure and pharmacological effects in a standardized animal model.’ HNO 39 (1991) pp. 48-54. |
| Hosemann, W.G. et al. ‘Minimally Invasive Endonasal Sinys Surgery’ Thieme, Stuttgart, New York (2000). |
| Hosemann, M.E. et al. ‘Normal Wound Healing of the Paranasal Sinuses—Clinical and Experimental Investigations’ Eur Arch Otohinolarygol. vol. 248, (1991) pp. 390-394. |
| Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6. |
| Hybels, R.L. ‘Transillumination During Osteoplastic Frontal Sinusotomy’ The Laryngoscope, vol. 91 (Sep. 1981) pp. 1560. |
| Ijaduola, T.G.A. ‘Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery’ Ther Journal of Laryngology and Otology. (1989) vol. 103. pp. 375.378. |
| Ingals, E.F. ‘New Operation and Instruments for Draining the Frontal Sinus’ Ann. Otol. Rhinol. Layyngol. vol. 14 (1905) pp. 644-649. |
| Iro, H. et al., ‘A New Device for Frontal Sinus Endoscopy: First Clinical Report’ Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616. |
| Jacobs, J.B. ‘100 Years of Frontal Sinus Surgery’ Laryngoscope. vol. 107 (1997) pp. 1-36. |
| K-Splint Internal Nasal Splints; Jan. 25, 2007; www.invotec.net/rhinology/ksplint.html. |
| Kennedy, D.W., M.D. et al. ‘Diseases of the Sinuses: Diagnosis and Management’ (Copyright 2001) by B.C. Decker Inc. |
| Kingdom, T.T. et al. ‘Image-Guided Surgery of the Sinuses: Current Technology and Applications’ Otolaryngol. Clin North Am. vol. 37, No. 2 (Apr. 2004) pp. 381-400. |
| Klossek, J.M. et al. ‘Local Safety of Intranasal Trimcinolone Acentonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis’ Rhinology. vol. 39, No. 1 (2001) pp. 17-22. |
| Kozlov et al. ‘Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters’ Rhinology (1996) vol. 34, pp. 123-124. |
| Kuhn, et al. ‘The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation’ Operative Techniques in Otolaryngology—Head and Neck Surgery. vol. 2, No. 4 (1991) pp. 226-231. |
| Laliberte, F. et al. ‘Clinical and Pathologic Methods to Assess the Long-Term Safety of Nasal Corticosteroids’ Allergy. vol. 55, No. 8 (2000) pp. 718-722. |
| Lang, E.V., et al., ‘Access Systems for Puncture at an Acute Angle’ J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713. |
| Lanza, D.C. ‘Postoperative Care and Advoiding Frontal Recess Stenosis’ Internatinal Advanced Sinus Symposium (Jul. 21-24, 1993). |
| Large, G.C. ‘Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis’ Canad. M.A.J. (1958) vol. 79 pp. 15-16. |
| Lund, V.J. ‘Maximal Medical Therapy for Chronic Rhinosinusitis’ Otolaryngol Clin N. Am. vol. 38 (2005) pp. 1301-1310. |
| Maran, A.G.D. et al. ‘The Use of the Foley Balloon Catheter in the Tripod Fracture’ J. Laryngol. Otol. (1971) vol. 85, Issue 9, pp. 897-902. |
| May, M. et al. ‘Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach’ Op Tech Otolaryngo Head Neck Surgery. 6 (1995) pp. 184-192. |
| Medtronic, xomed.com-MicroFrance Catalog Browser. Www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 (Dec. 31, 2003) pp. 1-2. |
| Mehan, V.K. et al., ‘Coronary Angioplasty through 4 French Diagnostic Catheters’ Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26. |
| Mellor, J.M. et al. ‘Synthesis of Trifluromethylnaphthalenes’ Tetrahedron. vol. 56 (2000) pp. 10067-10074. Elsevier Science Ltd. |
| Metson, R., et al., ‘Endoscopic Treatment of Sphenoid Sinusitis’ Otolaryngol. Head Neck Surg. (1996) vol 114, No. 6 pp. 736-744. |
| Metson, R. ‘Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study’ Laryngoscope. vol. 106, Issue 1, Supplement 77 (Jan. 1996) pp. 1-18. |
| Miller, et al. ‘Management of Fractures of the Supraorbital Rim’ Journal of Trauma. vol. 18, No. 7 (Jul. 1978) pp. 507-512. |
| Min, Y-G et al. ‘Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer’ Laryngoscope. vol. 105 (Aug. 1995) pp. 835-842. |
| Mols, B. ‘Movable Tool Tip for Keyhole Surgery’ Delft Outlook, vol. 3 (2005) pp. 13-17. |
| Mooney, M.R. et al., ‘Monorail™ Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System’ Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119. |
| Moriguchi, T. et al. ‘Additional-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins’ J. Org. Chem. vol. 60, No. 11 (1995) pp. 3523.3528. American Chemical Society. |
| Nasal Surgery and Accessories, Jan. 25, 2007; www.technologyforlife.com.au/ent/nasal.html. |
| Park, K. et al. ‘Biodegradable Hydrogels for Durg Delivery’ (1993) Technomic Publishing Inc. Lancaster. |
| Piccirillo, J.F. et al. ‘Physchometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome test (SNOT-20)’ Copyright 1996 Washington University, St. Louis, MO. |
| Piers, et al. ‘A Flexible Distal Tip with Two Degrees of Freedom for Enhanced Dexterity in Endoscopic Robot Surgery’ Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274. |
| Podoshin, L et al. ‘Balloon Technique for Treatment of Frontal Sinus Fractures’ The journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161. |
| Pownell, P.H. et al., ‘Diagnostic Nasal Endoscopy’ plastic & Reconstructive Surgery (1997) vol. 99, Iss5 pp. 1451-1458. |
| Prince, et al. ‘Analysis of the Intranasal Distribution of Ointment’ J Otolaryngol. vol. 26 (1997) pp. 357-360. |
| Ramsdale, D.R., Illustrated Coronary Intervention: A case-oriented approach, (2001) Martin Dunitz Ltd. pp. 1-5. |
| Ritter, F.N. et al., Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81. |
| Robison, J. Mathews, M.D. ‘Pressure Treatment of Maxillary Sinusitis’ J.A.M.A. (May 31, 1952) pp. 436-440. |
| Robison, J. Mathews, M.D. ‘Pressure Treatment of Purulent Maxillary Sinusitis’ Texas State Journal of Medicine (May 1952) pp. 281-288. |
| St. Croix et al. ‘Genes Expressed in Human Tumor Endothelium’ Science, vol. 289 (May 15, 2000) pp. 1197-1202. |
| Sama, A., et al., ‘Current Opinions on the Surgical Management of Frontal Sinus Disease’ ENT News. Www.pinpointmedical.com/ent-news (2009) vol. 17, No. 6 pp. 60-63. |
| Sanborn, T.A. et al., ‘Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluroscopic Guidance’ Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266. |
| Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon Washington 98070 USA. |
| Saxon, R.R. et al., ‘Technical Aspects of Accessing the Portal Vein During the TIPS Procedure’ J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744. |
| Schaefer, S.D., M.D. ‘Rhinology and Sinus Disease: A Problem-Oriented Approach’ (Copyright 1988) by Mosby, Inc. |
| Schneider, Pfizer Ad for Softip [date of publication unknown]. |
| Shah, N.J. et al., ‘Endoscopic Pituitary Surgery—A Beginner's Guide’ Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78. |
| Shah, N.J. ‘Functional Endoscopic Sinus Surgery’ (1999); found at bhj.org/journal/1999—4104—oct99/sp—659.htm. |
| Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems. |
| Sinusitis, Maxillary, Acute Surgical Treatment. Http://www.emedicine.com/ent/topic340.htm. Aug. 29, 2006. pp. 1-11. |
| Stammberger, et al. Chapter 3 ‘Special Endoscopic Anatomy of the Lateral Nasal Wall and Ethmoidal Sinuses’ Functional Endoscopic Sinus Surgery. (1991) Ch. 3, pp. 49-87. |
| SurgTrainer Product Information 2003, Surg Trainer, Ltd. Ibaraki, Japan. |
| SurgTrainer Product Information ‘Incisive Human Nasal Model for ESS Training’ SurgTrainer, Ltd. Ibaraki, Japan (2004) www1.accsnet.ne.jp/˜juliy/st/en/partslist.html. |
| Tabor, M.H. et al., ‘Symptomatic Bilateral Duct Cysts in a Newborn—Rhinoscopic Clinic’ Ear, Nose & Throat Journal (2003) www.findarticles.com/p/articles/mi—m0BUM/is—2—82/ai—98248244 pp. 1-3. |
| Terumo. Medi-Tech. Boston Scientific. (1993) Ad of Glidewire. |
| Weber, R. et al., ‘Videoendoscopic Analysis of Nasal Steroid Distribution’ Rhinology. vol. 37 (1999) pp. 69-73. |
| Weiner, R.I., D.O., et al., ‘Development and Application of Transseptal Left Heart Catheterization’ Cathet. Cardiovasc. Diagn. (1988) vol. 15, No. 2, pp. 112-120. |
| Wiatrak, B.J., et al., ‘Unilateral Choanal Atresia: Initial Presentation and Endoscopic Repair’ International Journal of Pediatric Otorhinolaryngology (1998) vol. 46, pp. 27-35. |
| Woog, et al. ‘Paranasal Sinus Endoscopy and Orbital Fracture Repair’ Arch Ophthalmol. vol. 116 (May 1998) pp. 688-691. |
| Wormald, P.J., et al., ‘The ‘Swing-Door’ Technique for Uncinectomy in Endoscopic Sinus Surgery’ The Journal of Laryngology and Otology (1998) vol. 112, pp. 547-551. |
| Xomed-Treace. Bristol-Myers Squibb. Ad for Laser Shield II. Setting the Standards for Tomorrow. [date of publication unknown]. |
| Yamauchi, Y. et al., ‘Development of a Silicone Model for Endoscopic Sinus Surgery’ Proc International Journal of Computer Assisted Radiology and Surgery vol. 99 (1999) p. 1039. |
| Yamauchi, Y., et al., ‘A Training System for Endoscopic Sinus Surgery with Skill Evaluation’ Computer Assisted Radiology and Surgery (2001) with accompanying copy of poster presentation. |
| Yanagisawa et al. ‘Anterior and Posterior Fontanelles.’ Ear, Nose & Throat Journal (2001) vol. 80. pp. 10-12. |
| Zimarino, M., M.D., et al., ‘Initial Experience with the EuropassTM: A new Ultra-Low Profile monorail Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1994) vol. 33, No. 1, pp. 76-79. |
| Australian Office Action, Examiners First Report dated Apr. 8, 2010 for Application No. AU 2005274794. |
| Australian Office Action, Examiners First Report dated Dec. 9, 2011 for Application No. AU 2006292818. |
| Chinese Office Action, First Office Action dated Nov. 5, 2012 for CN 20090137396.1. |
| Chinese Search Report dated Oct. 29, 2012 for Application No. CN 200980137396.1. |
| Chinese Search Report dated Jan. 11, 2013 for Application No. CN 200980152995.0. |
| Chinese Office Action, First Office Action dated Jan. 29, 2013 for CN 200980152995.1. |
| European Communication dated Sep. 4, 2008 for Application No. EP 05773189. |
| European Communication dated Jun. 19, 2009 for Application No. EP 05773189. |
| European Communication dated Aug. 1, 2012 for Application No. EP 06784759.0. |
| European Communication dated Aug. 24, 2012 for Application No. EP 05798331.4. |
| European Communication dated Nov. 9, 2012 for Application No. EP 07750248.2. |
| European Communication dated Apr. 19, 2012 for Application No. EP 08746715.5. |
| European Communication dated Jan. 1, 2013 for Application No. EP 08746715.5. |
| European Communication dated Apr. 11, 2013 for Application No. EP 05778834.1. |
| European Communication dated May 10, 2013 for Application No. EP 06751637.7. |
| European Exam Report dated Feb. 22, 2006 for Application No. EP 02716734.5. |
| European Exam Report dated Feb. 8, 2007 for Application No. EP 02716734.5. |
| European Search Report and Written Opinion dated Sep. 11, 2009 for Application No. EP 06815174. |
| European Search Report dated Mar. 16, 2010 re Application No. EP 06718986. |
| European Search Report dated Sep. 27, 2011 for Application No. EP 10182961. |
| European Search Report dated Sep. 29, 2011 for Application No. EP 10182893. |
| European Search Report dated Jul. 23, 2012 for Application No. EP 12162709. |
| European Search Report dated Jul. 24, 2012 for Application No. EP 12162712. |
| European Search Report dated Aug. 31, 2012 for Application No. EP 12173295. |
| European Search Report dated Oct. 10, 2012 for Application No. EP 12175607. |
| European Search Report dated Nov. 22, 2012 for Application No. EP 12182993. |
| European Search Report dated Dec. 5, 2012 for Application No. EP 12182998. |
| European Search Report dated Jan. 9, 2013 for Application No. EP 12183000. |
| European Search Report dated Jan. 11, 2013 for Application No. EP 12183002. |
| European Search Report dated Aug. 13, 2013 for Application No. EP 13172140. |
| European Search Report dated Sep. 9, 2013 for Application No. EP 13179223. |
| Partial European Search Report dated Sep. 20, 2007 for Application No. EP 07252018. |
| Partial European Search Report dated Mar. 25, 2008 for Application No. EP 07252018. |
| Supplemental Partial European Search Report dated Jun. 2, 2008 for Application No. EP 05773189. |
| Supplemental Partial European Search Report dated Jul. 1, 2009 for Application No. EP 06815285. |
| Supplemental Partial European Search Report dated Nov. 19, 2010 for Application No. EP 06751637. |
| Supplemental European Search Report dated Jan. 29, 2010 for Application No. EP 07836108. |
| Supplemental European Search Report dated Feb. 2, 2010 for Application No. EP 07836109. |
| Supplemental European Search Report dated Feb. 17, 2010 for Application No. EP 07836110. |
| Supplemental European Search Report dated Mar. 1, 2010 for Application No. EP 05778834. |
| Supplemental European Search Report dated Mar. 16, 2010 for Application No. EP 06718986. |
| Supplemental European Search Report dated Jun. 22, 2010 for Application No. EP 06784759. |
| Supplemental European Search Report dated Sep. 23, 2010 for Application No. EP 08746715. |
| Supplemental European Search Report dated Jan. 28, 2011 for Application No. EP 07777004. |
| Supplemental European Search Report dated Mar. 31, 2011 for Application No. EP 05798331. |
| Supplemental European Search Report dated Aug. 30, 2011 for Application No. EP 06800540. |
| Supplemental European Search Report dated Sep. 29, 2011 for Application No. EP 07750248. |
| PCT Search Report dated Nov. 30, 2009 for Application No. PCT/US2009/057203. |
| International Preliminary Report on Patentability dated Aug. 7, 2006 for Application No. PCT/US05/25371. |
| International Preliminary Report on Patentability and Written Opinion dated Sep. 25, 2007 for Application No. PCT/US06/002004. |
| International Preliminary Report on Patentability dated Feb. 15, 2008 for Application No. PCT/US05/13617. |
| International Preliminary Report on Patentability and Written Opinion dated Nov. 18, 2008 for Application No. PCT/US07/11449. |
| International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2009 for Application No. PCT/US07/021170. |
| International Preliminary Report on Patentability and Written Opinion dated May 5, 2009 for Application No. PCT/US06/036960. |
| International Preliminary Report on Patentability and Written Opinion dated Oct. 13, 2009 for Application No. PCT/US08/059786. |
| International Preliminary Report on Patentability and Written Opinion dated Oct. 27, 2009 for Application No. PCT/US08/061343. |
| International Preliminary Report on Patentability dated Jun. 29, 2011 for Application No. PCT/US2009/069143. |
| International Search Report dated Jun. 3, 2002 for Application No. PCT/EP02/01228. |
| International Search Report and Written Opinion dated Apr. 10, 2006 for Application No. PCT/US05/25371. |
| International Search Report dated May 8, 2007 for Application No. PCT/US2006/16026. |
| International Search Report dated Aug. 17, 2007 for Application No. PCT/US05/013617. |
| International Search Report dated Aug. 29, 2007 for Application No. PCT/US06/002004. |
| International Search Report dated Sep. 25, 2007 for Application No. PCT/US06/037167. |
| International Search Report dated Oct. 19, 2007 for Application No. PCT/US07/003394. |
| International Search Report dated May 29, 2008 for Application No. PCT/US07/021170. |
| International Search Report dated May 29, 2008 for Application No. PCT/US07/021922. |
| International Search Report dated Jul. 1, 2008 for Application No. PCT/US06/022745. |
| International Search Report dated Jul. 3, 2008 for Application No. PCT/US2006/029695. |
| International Search Report dated Jul. 7, 2008 for Application No. PCT/US07/016213. |
| International Search Report dated Jul. 8, 2008 for Application No. PCT/US07/011474. |
| International Search Report dated Jul. 17, 2008 for Application No. PCT/US06/036960. |
| International Search Report and Written Opinion dated Jul. 21, 2008 for Application No. PCT/US05/033090. |
| International Search Report dated Aug. 25, 2008 for Application No. PCT/US2008/000911. |
| International Search Report dated Sep. 10, 2008 for Application No. PCT/US07/016212. |
| International Search Report and Written Opinion dated Sep. 12, 2008 for Application No. PCT/US07/16214. |
| International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/059786. |
| International Search Report dated Oct. 15, 2008 for Application No. PCT/US2008/061048. |
| International Search Report dated Nov. 30, 2009 for Application No. PCT/US2009/057203. |
| International Search Report dated Dec. 10, 2009 for Application No. PCT/US2009/052236. |
| International Search Report dated Dec. 16, 2009 for Application No. PCT/US2009/050800. |
| International Search Report dated Mar. 31, 2010 for Application No. PCT/US2009/069143. |
| International Search Report dated Jul. 8, 2010 for Application No. PCT/US2010/027837. |
| International Search Report and Written Opinion dated Oct. 6, 2010 for Application No. PCT/US2010/040548. |
| International Search Report dated Mar. 25, 2011 for Application No. PCT/US2010/062161. |
| International Search Report dated Mar. 28, 2011 for Application No. PCT/US2010/061850. |
| International Search Report dated Mar. 31, 2011 for Application No. PCT/US2010/060898. |
| International Search Report dated Mar. 31, 2011 for Application No. PCT/US2009/069143. |
| International Search Report dated Aug. 9, 2011 for Application No. PCT/US2011/038751. |
| International Search Report dated May 18, 2012 for Application No. PCT/US2011/052321. |
| Japanese Office Action, Examiner's Decision of Refusal dated Oct. 18, 2011 for Application No. JP 2007-509632. |
| Japanese Office Action, Notification of Reasons for Refusal dated Apr. 26, 2011 for Application No. JP 2007-532485. |
| Japanese Office Action, Notification of Reasons for Refusal dated Jan. 24, 2012 for Application No. JP 2007-532485. |
| Japanese Office Action, Notification of Reasons for Refusal dated Aug. 16, 2011 for Application No. JP 2008-516013. |
| Japanese Office Action, Notification of Reasons for Refusal dated Nov. 8, 2011 for Application No. JP 2008-524250. |
| Japanese Office Action, Notification of Reasons for Refusal dated Jun. 25, 2013 for Application No. JP 2012-131840. |
| Russian Office Action dated Sep. 28, 2012 for Application No. RU 2011130530. |
| Russian Office Action dated Mar. 19, 2013 for Application No. RU 2011130530. |
| USPTO Office Action dated Sep. 16, 2005 for U.S. Appl. No. 10/259,300. |
| USPTO Office Action dated Jul. 7, 2006 for U.S. Appl. No. 10/259,300. |
| USPTO Office Action dated Feb. 13, 2007 for U.S. Appl. No. 10/259,300. |
| USPTO Office Action dated Oct. 9, 2007 for U.S. Appl. No. 10/259,300. |
| USPTO Office Action dated Jan. 24, 2008 for U.S. Appl. No. 10/259,300. |
| USPTO Office Action dated Oct. 6, 2008 for U.S. Appl. No. 10/259,300. |
| USPTO Office Action dated May 29, 2007 for U.S. Appl. No. 10/912,578. |
| USPTO Office Action dated Nov. 14, 2007 for U.S. Appl. No. 10/912,578. |
| USPTO Office Action dated Dec. 10, 2007 for U.S. Appl. No. 10/912,578. |
| USPTO Office Action dated Oct. 18, 2007 for U.S. Appl. No. 11/037,548. |
| USPTO Office Action dated Dec. 6, 2007 for U.S. Appl. No. 11/037,548. |
| USPTO Office Action dated Apr. 9, 2008 for U.S. Appl. No. 11/037,548. |
| USPTO Office Action dated Nov. 28, 2007 for U.S. Appl. No. 11/234,395. |
| USPTO Office Action dated Sep. 12, 2008 for U.S. Appl. No. 10/829,917. |
| USPTO Office Action dated Mar. 18, 2009 for U.S. Appl. No. 10/829,917. |
| USPTO Office Action dated Nov. 9, 2009 for U.S. Appl. No. 10/829,917. |
| USPTO Office Action dated Oct. 29, 2008 for U.S. Appl. No. 11/347,147. |
| USPTO Office Action dated Feb. 4, 2009 for U.S. Appl. No. 11/347,147. |
| USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 11/347,147. |
| USPTO Office Action dated Nov. 7, 2008 for U.S. Appl. No. 10/944,270. |
| USPTO Office Action dated Jan. 28, 2009 for U.S. Appl. No. 10/944,270. |
| USPTO Office Action dated Apr. 21, 2009 for U.S. Appl. No. 10/944,270. |
| USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/117,582. |
| USPTO Office Action dated Mar. 3, 2009 for U.S. Appl. No. 12/117,582. |
| USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,582. |
| USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/118,931. |
| USPTO Office Action dated Mar. 4, 2009 for U.S. Appl. No. 12/118,931. |
| USPTO Office Action dated Jul. 30, 2009 for U.S. Appl. No. 12/118,931. |
| USPTO Office Action dated Nov. 25, 2008 for U.S. Appl. No. 12/117,961. |
| USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,961. |
| USPTO Office Action dated Dec. 5, 2008 for U.S. Appl. No. 12/120,902. |
| USPTO Office Action dated Oct. 21, 2009 for U.S. Appl. No. 12/120,902. |
| USPTO Office Action dated Mar. 17, 2009 for U.S. Appl. No. 11/690,127. |
| USPTO Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/804,309. |
| USPTO Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/926,326. |
| USPTO Office Action dated Aug. 28, 2009 for U.S. Appl. No. 11/150,847. |
| USPTO Office Action dated Dec. 29, 2009 for U.S. Appl. No. 11/193,020. |
| USPTO Office Action dated May 13, 2009 for U.S. Appl. No. 11/193,020. |
| Australian Office Action, Examiner's First Report dated Mar. 5, 2014 for Application No. AU 2011305612. |
| Chinese Office Action, Second Office Action dated Jun. 15, 2011 for Application No. CN 200780042221.3. |
| European Communication dated Jun. 29, 2010 for Application No. EP 0783610934. |
| European Communication date Jul. 20, 2010 for Application No. EP 07836110. |
| European Search Report dated Oct. 10, 2012 for Application No. EP 12175585. |
| International Preliminary Report on Patentability dated Mar. 26, 2013 for Application No. PCT/US2011/052321. |
| Khomutov, S.M., et al, ‘Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description’ Pharmaceutical Chemistry Journal. vol. 35, No. 11 (Nov. 2001) pp. 627-629. |
| Sobol, et al, ‘Sinusitis, Maxillary, Acute Surgical Treatment.’ eMedicine, Retrieved from the Internent: <<http://emedicine.medscape.com/article/862030-print>> (Nov. 16, 2010) pp. 1-11. |
| The Operating Theatre Journal (www.otjonlie.com) ‘Disposable Medical Device for Wound Disclosure/The Tristel Purple Promotion—A Collaboration between Tristel PLC and Karl Storz Endoscopy (UK) Ltd.’ (Aug./Sep. 2005) p. 4. |
| Chinese Examiner's Report dated Nov. 25, 2014 for Application No. CN 201180046789.7. |
| International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/061343. |
| International Search Report and Written Opinion dated Oct. 1, 2008 for Application No. PCT/US07/011449. |
| Partial International Search Report dated Feb. 7, 2012 for Application No. PCT/US2011/052321. |
| USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 10/829,917. |
| U.S. Appl. No. 60/844,874, filed Sep. 15, 2006. |
| U.S. Appl. No. 60/922,730, filed Apr. 9, 2007. |
| U.S. Appl. No. 61/052,413, filed May 12, 2008. |
| U.S. Appl. No. 61/084,949, filed Jul. 30, 2008. |
| U.S. Appl. No. 11/789,705, filed Apr. 24, 2007. |
| U.S. Appl. No. 11/804,308, filed May 16, 2007. |
| U.S. Appl. No. 11/804,309, filed May 16, 2007. |
| Chinese Fourth Office Action dated Aug. 24, 2012 for Application No. CN 200780042221.3, 9 pages. |
| Chinese Search Report dated Nov. 13, 2014 for Application No. CN 201180045789.7, 2 pages. |
| Chinese First Office Action dated Nov. 25, 2014 for Application No. CN 201180045789.7, 4 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20090187098 A1 | Jul 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10829917 | Apr 2004 | US |
| Child | 12355492 | US | |
| Parent | 11522497 | Sep 2006 | US |
| Child | 10829917 | US |
